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ABSTRACT
Current cancer immunotherapies include immune checkpoint inhibitors, adoptive cellular
therapy, and cancer vaccines. While some of these therapies have met with great clinical success,
they are associated with several limitations. Oncolytic virotherapy (OVT) has emerged as a bona
fide promising immunotherapy, that uses viral infection to liberate tumor antigens in an
immunogenic context to promote the development of anti-tumor immune responses. At present,
Talimogene laherparepvec (T-VEC; Imlygic™), a modified type 1 herpes simplex virus (HSV-1)
is the only FDA approved OVT for human cancer treatment (melanoma). While T-VEC is
associated with limited response rates, its modest efficacy supports the continued development of
novel OVT viruses.
First, we investigated the efficacy of a the live-attenuated vaccine strain HSV-1(VC2), as an
OVT in a syngeneic B16F10-derived mouse model of melanoma. VC2 possesses mutations in
two of its viral envelope proteins: glycoprotein K and UL20, rendering the virus unable to enter
into neurons via their axonal termini both in vitro and in vivo. Intratumoral treatment of mice
engrafted with modified B16F10 melanoma cells with VC2, slowed tumor growth rates and
significantly prolonged survival. VC2-treated mice that survived initial tumor engraftment were
able to reject a second tumor engraftment challenge We found that VC2 treatment resulted in
increased intratumoral T cell infiltration, and a decrease in immunosuppressive regulatory T
cells.
We hypothesized that VC2 may be used to deliver tumor associated antigens to promote
enhanced anti-tumor directed responses. We tested this hypothesis in mice using chicken
ovalbumin (OVA) as a surrogate tumor-associated antigen in the B16cOVA melanoma models.
VC2 was engineered to express a fragment of OVA fused to the viral VP26 capsid protein.
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Vaccination with VC2-OVA induced both an OVA-specific T cell responses. Intradermal
vaccination with VC2-OVA conferred significant protection and prolonged the survival of mice
which had been challenged with B16cOVA cells. Therapeutic treatment with VC2-OVA resulted
in reduced lung colonization of tumor cells in mice challenged intravenously with B16cOVA
cells. These findings confirm the remarkable efficacy, safety, and immunogenicity profiles of
VC2. Importantly, these results demonstrate that VC2 holds promise for the delivery of
heterologous antigens for personalized cancer immunotherapy.
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CHAPTER 1
INTRODUCTION TO HERPES SIMPLEX VIRUS AND ONCOLYTIC
VIROTHERAPY
1.1. General description Herpesviridae family
Herpesviruses belong to the Herpesviridae family, subfamily Alphaherpesvirinae, and genus
Simplexvirus [1]. Herpesviruses are characterized by a large, linear double stranded DNA
genome constituted of approximately 125–295 kilobase pairs (kbp). Their genome is enclosed by
a T = 16 icosahedral capsid, approximately 125 nm in diameter, and is made of capsomers. The
capsid is surrounded by layers of proteins called the tegument which is wrapped in a lipid bilayer
envelope [1]. The virus envelope is derived from host cell membranes and contains a number of
different viral glycoproteins (Figure 1.1).1
In the past, members of herpesviruses were grouped into subfamilies on the basis of their
shared morphology. Within the last two decades, sequencing technologies provided a wealth of
information about the viral genetic content and genome organization, which are used for modern
classification and nomenclature [1-3]. The family Herpesviridae is grouped into three
subfamilies namely: Alpha-, Beta-, or Gammaherpesvirinea [1-3]. The shared extensive
equivalences in their gene complements and together with other molecular phylogenetic analysis
suggests that the Herpesviridae subfamilies descended from a common ancestral herpesvirus
species [1-3]. Despite their morphological similarities, they differ greatly in their host range and
the characteristics of their life cycle.

Sections 1.6 – 1.11 were previously published as: Uche IK, Kousoulas KG, Rider PJF. The
Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor
Microenvironment. Viruses 2021, 13, 1200. https://doi.org/10.3390/v13071200
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Figure 1.1. Schematic structure of a herpesvirus. The linear double-stranded DNA genome is
enclosed in an icosahedral capsid, overlaid by a tegument and surrounded by a lipid envelope
containing different glycoproteins.
Alphaherpesviruses are defined on the basis of a variable host range, shorter reproductive
cycle, rapid growth, high cytotoxic effects and the ability to establish latency primarily, but not
exclusively, in sensory ganglia. Alphaherpesviruses that infect humans includes herpes simplex
viruses 1 and 2 (HSV-1 and HSV-2) and varicella zoster virus (VZV) which represent human
herpesvirus (HHV) 1, 2, and 3 respectively (Table1) [4, 5]. Betaherpesviruses are characterized
by their narrow host range, longer reproductive cycle, and slower growth. Infection with
betaherpesviruses results in cell enlargement (cytomegalia) and can become latent in secretory
glands, lymphoreticular cells, and in other tissues such as the kidneys. Human cytomegalovirus
(HCMV) or HHV-5, HHV-6 (A and B), and HHV-7 represents members of this subfamily that
causes infections in human [4, 5]. Like betaherpesviruses, gammaherpesviruses grow slowly and
exhibit a more restricted host range. They infect lymphocytes and establish latency in lymphoid
tissues. Members of the gammaherpesvirus subfamily include Epstein-Barr virus (EBV) or
HHV-4 and Kaposi´s sarcoma-associated herpesvirus (KSHV) referred to as HHV-8 [4, 5].
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Clinical complications associated with members of each of the three sub-families of
herpesviruses are listed in Table 1 [5].
Table 1.1. Classification and complications of human herpesviruses.
Subfamily
Name
Genome Primary
Clinical pathology
size (kb) target
Alphaherpesviruses

Betaherpesviruses

Herpes
simplex 1
(HSV-1) or
HHV-1

~152

Herpes
~154
simplex 2
(HSV-2) or
HHV-2
Varicella
~125
zoster virus
(VZV) or
HHV-3
Human
~235
cytomegalovir
us (HCMV)
or HHV-5

Human
herpesvirus
6A (HHV6A)
Human
herpesvirus
6B (HHV-6B)

~160

Human
herpesvirus 7
(HHV-7)

~145

Mucoepeithelia Cold sores,
l cells (mainly encephalitis,
orofacial tract) herpetic whitlow,
herpes gladiatorum,
and herpes keratitis
and genital lesions.
Mucopeithelial Genital lesions.
cells (mainly
genital tract)

Sensory
nerve
ganglia

Mucoepithelial
cells

Chickenpox and
shingles.

Sensory
nerve
ganglia

Epithelial cells,
monocytes,
and
lymphocytes.

Infectious
mononucleosis-like
syndrome, retinitis,
hepatosplenomegal
y.

T cells

Roseola infantum
(exanthem subitum)
(roseola) and with
rejection of
transplanted
kidneys.

Monocy
tes,
kidney
epithelia
l cells,
and
others
T cells

T cells

Associated with
T cells
Roseola infantum
(exanthem subitum)
and febrile illness.

~162

table cont’d.
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Site of
latency

Sensory
nerve
ganglia

Subfamily

Name

Gammaherpesviruses EpsteinBarr virus
(EBV) or
HHV-4

Genome Primary
size (kb) target
~172
B cells and
epithelial
cells

Clinical pathology

Site of
latency
B cells

Infectious
mononucleosis.
Also associated
with Burkitt’s
lymphoma,
Hodgkin diseases,
post-transplant
lymphoproliferative
syndrome (PTLD),
and nasopharyngeal
carcinoma.
Lymphocytes Kaposi’s sarcoma,
B cells
and more
primary effusion
lymphoma, some
types of
multicentric
Castleman’s
disease.

Kaposi´s
~165kb
sarcomaassociated
herpesvirus
(KSHV) or
HHV-8

1.2. Herpes simplex virus type 1 life cycle
Herpesviruses enter cells via two major pathways: (a) by fusion of their viral envelope with
the plasma membrane or (b) through receptor mediated endocytosis which may be pH dependent
or independent depending on the cell type [6-9]. Herpesviruses utilize a multicomponent
membrane fusion apparatus that consists of at least three proteins, glycoprotein B (gB), gH, and
gL, to mediate entry to host cells [6]. These glycoproteins are conserved in all herpesvirus, with
the highest level sequence similarity seen in gB [6]. Also the gH/gL heterodimer has been
identified as a common tropism determining protein complex in herpesviruses [10].
Initial attachment of the HSV to cellular membranes is mediated by the binding of
glycoproteins gB and gC to glycosaminoglycans (GAGs) mainly heparan sulfate (HS) [11, 12].
This is followed by gD-mediated tight binding to at least one of three known entry receptors
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which includes: (a) herpesvirus entry mediator (HVEM or HveA), a member of the tumor
necrosis factor (TNF) receptor family [13] (b) nectin-1 (HveC) or nectin-2 (HveB), two cell
adhesion molecules which are members of the immunoglobulin superfamily [14-16] and (c)
specific sites in heparin sulfate produced by certain isoforms of 3-O-sulfotransferase (3-OS HS)
[17]. There are two HSV serotypes, HSV-1 and HSV-2. These serotypes are different in their
usage of gD receptors [17], and this perhaps influences the difference in their pathogenesis.
HVEM and nectin-1 are excellent entry receptors for both serotypes, whereas nectin-2 is a better
receptor for HSV-2 than HSV-1 [16]. On the other hand, HSV-1 and not HSV-2 appears to use
3-OS HS [18]. A list of cell line with known gD receptors have been reviewed in [19]. It is
noteworthy that these cell surface molecules bind to gD independently of each other during HSV
entry. Furthermore, the human and mouse forms of these receptors are similar but not identical in
their HSV entry activities. This may explain the reason why both HSV-1 and HSV-2 can infect
mice.
The sequential binding of gD triggers the fusion of the viral envelope with the cell surface
membrane and subsequent viral entry into the cell. However, the molecular mechanism behind
this model is not fully understood. It is thought that the binding of the receptor by gD somehow
results in a conformational change in gD, which in turn changes the conformation of the gH/gL
heterodimer, which ultimately activates the fusogenic activity of gB [10, 20]. It remains
somewhat puzzling that HSV requires gD to initiate fusion, whereas other herpesviruses like
VZV can do without it. Nevertheless, it is conceivable that the involvement or presence gD
maybe one of the reasons why HSV have a large host range, since gD is capable of binding to at
least three distinct entry receptors which is expressed by different human and animal cells.
Without doubt, there is a possibility that other accessory proteins other than gD, can control gB-
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mediated membrane fusion. At least this idea emerge in part from studies done by our laboratory
where we found that deletion of amino acids 31–68 within the amino terminus of gK inhibited
virus-induced fusion and entry [21, 22].
Upon cell entry, HSV releases its capsid and tegument proteins into the host cytoplasm
which are transported to the nucleus. This transportation occurs along the microtubules and is
mediated by a dynein-dynactin motor complex. Vaccinia virus and adenovirus are examples of
other viruses that have been reported to utilize the dynein-dynactin motor complex for
intracellular transport [23, 24]. The incoming HSV capsid docks at the nuclear pore complexes
(NPCs), and the viral genome is deposited into the nucleus [25]. This is followed by an
orchestrated cascade expression of three subsets of viral genes: immediate early (IE), early (E),
and late (L) genes. The transcription of the IE genes including infected cell protein (ICP) 0,
ICP4, ICP27, and ICP47 is mediated by infected host cell RNA polymerase II. Specifically,
VP16, a transactivator tegument protein, in coordination with cellular proteins Oct-1 and HCF-1
induces the transcription of IE genes [26]. IE genes expression, in turn promotes the transcription
of E genes, that mainly encode enzymes involved in viral DNA synthesis and replication. The
expression of the E genes in turn transactivates the L genes, which encode structural proteins
[26]. The L genes are expressed after the onset of DNA replication in contrast to the expression
of the E genes which are not dependent on viral DNA replication [27]. An identical model has
been proposed for EBV; however, it is still a matter of debate whether EBV late genes
expression is dependent on viral templates [28, 29]. Further studies are required to fully
understand the mechanisms by which transcription and replication are coupled during HSV
infection.
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Structural proteins and new viral genomes are packaged to form capsids. As the capsid
translocate to the cytoplasm, it buds through the inner nuclear membrane to form enveloped viral
particles (primary envelopment), which further lose their envelopes as they fuse with the outer
nuclear membrane. Naked capsids in the cytoplasm are then re-enveloped (secondary
envelopment) and acquire other glycoproteins by budding into vesicles of the Trans-Golgi
Network (TGN) before exiting from the cell [26]. Like all other herpesviruses, HSV exhibits two
alternative infection cycles, lytic and latent cycle. The inefficient transport of VP16 to neuronal
cell body may favor HSV latent cycle, where the viral DNA persists in the nucleus in an
episomal form, in contrast to the lytic cycle as described above [26, 30]. Furthermore, available
evidence strongly supports that the expression of HSV genes during each infection cycle is
differentially regulated by chromatin structure [31].

7

Figure 1.2. Summary of HSV-1 life cycle. HSV enters the cell by fusion of their viral envelope
with the plasma membrane or through receptor mediated endocytosis. In the endocytic pathway,
the virion fuses with an endocytic vesicle and releases it nucleocapsid into the cytoplasm. The
nucleocapsid is transported to the nuclear pore and the viral DNA is released into the nucleus.
Inside the nucleus, replication of viral DNA and transcription of viral genes occurs, followed by
assembly of nucleocapsids. Primary envelopment occurs as the nucleocapsid buds through inner
nuclear membrane. Fusion with the outer nuclear membrane results in loss of this initial
envelope. The released naked capsids become re-enveloped and acquire other glycoproteins as
they bud through vesicles of the Trans-Golgi Network (TGN) and are released from the host cell.
1.3. Herpes simplex virus type 1 tropism
How herpesvirus restrict their host range both in vivo and in vitro is not fully understood.
Herpesvirus tropism is determined by specificity of viral receptor binding proteins and receptors.
In addition to these core requirements for fusion, other glycoproteins may also be involved in
viral entry. Our laboratory has demonstrated that gK, which is highly conserved among all
neurotropic alphaherpesviruses, is a viral tropism determinant required for HSV entry into
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neuronal cells through axonal termini [32, 33]. gK is a membrane glycoprotein encoded by the
UL53 gene and has important function in virion entry, cytoplasmic virion envelopment, and
virion egress [34]. gK forms a functional protein complex with the UL20 membrane protein
allowing the gK/UL20 protein complex to physically interact with the sole viral fusogenic
glycoprotein gB [34, 35]. The gK/UL20 protein complex is essential for HSV-1 fusion mediated
entry [21, 36]. Furthermore, we have previously shown that the UL20 protein affects cell surface
expression of gK [37]. Wang et al have also shown that UL20 is found in a heterodimeric form
with gK GODZ (also known as DHHC3), and this interaction is required for efficient virus
infectivity [38].
Mutating the N glycosylationsite N58A of the amino terminus of gK, resulted to an
extensive virus-induced cell fusion [39]. On the other hand, when amino acids 31-68 within the
amino terminus of gK is deleted, virus induced cell fusion and entry is inhibited, while entry via
endocytosis is not altered [32, 33]. The amino terminus of gK functions as a critical determinant
for virus entry into neurons via the axonal termini. We have shown that the HSV-1(McKrae)
gKΔ31-68 virus was unable to enter neurons via the axonal termini both in vitro and in vivo [32,
33]. Thus, gK plays an important role in the negative as well as the positive regulation of gBmediated membrane fusion phenomena. The HSV-1(VC2) attenuated virus contains a gKD31-68
mutation as well as a UL20D4–22 mutation, which inhibits the virus entry via fusion.
Vaccination with VC2 elicits strong humoral and cellular immune responses compared to its
parental strain HSV-1(F) [40-45].
A huge progress has been made to alter and retarget HSV tropism in an effort to develop
efficacious vaccines, effective gene therapies and oncolytic immunotherapies [46-51]. Laquerre
et al. were the first to successfully retarget HSV tropism [52]. Specifically, HSV-1 was
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engineered to express the erythropoietin (EPO) protein, by replacing the HS binding domain of
gC with an EPO ligand. Recombinant viruses encoding the EPO-gC chimeric protein
demonstrated significant reduction in binding activity to glycosaminoglycans (GAGs), while
they specifically bound to cells expressing the EPO receptor. In a similar method, gC of HSV-1
was engineered to express a preS1 active peptide (preS1ap) of hepatitis B virus (HBV) in order
to confer specific binding to hepatocytes [53]. Recombinant HSV-1 recombinant expressing the
gC-preS1ap fusion molecule demonstrated increased entry into hepatocytes, compared to
parental virus that was impaired in their binding activity to GAGs. While this recombinant
exhibited increased entry kinetics on hepatocytes, wild-type HSV-1 entry was even more
efficient [53]. This indicates that the preferred mode of entry in these cells involves the binding
of gD to one or more receptors expressed by hepatocytes.
In another example, Grandi et al replaced the HS-binding domain of gC with a His-tag
sequence in order to redirect the HSV vector to 293 6H cells expressing a cell surface pseudoHis-tag receptor [54]. The His-tagged virions exhibited a four-fold increase in binding efficiency
to the aforementioned cells. Furthermore, gC has also been manipulated to target an ionotropic
glutamate receptor, N-methyl-D-aspartate (NMDA) NR1 subunit, so that the virus infect NR1containing neuronal cells preferentially [55]. Collectively, these studies suggest that HSV could
be engineered to bind to non-HSV cell surface receptors without disrupting their fusogenic
properties. It is conceivable that utilizing retargeted HSV vectors for therapeutic purposes would
confer an enhanced specificity, efficacy, and safety. Greater details of how this novel approach is
used in developing oHSVs will be discussed more in details later.
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1.4. Herpes simplex virus pathogenesis
HSV-1 and HSV-2 share 83% nucleotide homology [56]. Although HSV-1 and HSV-2
are closely related viruses, they cause different disease symptoms. Both HSV-1 and HSV-2 are
transmitted through direct contact with a person who is actively shedding the virus. HSV-1 is the
causative agent of cold sores, encephalitis, herpetic whitlow, herpes gladiatorum, and herpes
keratitis (ocular herpes) (Table 1) [57, 58]. The complications of ocular HSV-1 infections are
also the leading cause of infectious blindness in the United States [59]. HSV-2 is primarily a
sexually transmitted disease and usually causes genital lesions [57], although recent studies
showed that HSV-1 infection can cause genital infection [60]. Both HSV-1 and HSV-2 produce
persistent lifelong infections by establishing latency in the nerve ganglia of the host. Both viruses
can subsequently reactivate from their latent ganglia reservoirs, resulting in virus shedding that
contributes to high transmission rates [57]. Moreover, it has been reported that the risk of
acquiring human immunodeficiency virus (HIV) infection is increased threefold in people with
genital HSV infection [61, 62]. Overall, it is estimated that 47.8% and 11.9% of people ages 14
to 49 in the United States are infected with HSV-1 and HSV-2 respectively [63].
1.5. Herpes simplex virus immune responses
Host immunity against HSV infection involve an interplay between the innate and
adaptive immune responses. As is the case with many infectious agents, the innate immune
system represents the first line of defense against HSV and plays an important role in the early
infection detection and for initiating cellular host countermeasures such as interferon (IFN)
responses [64, 65]. Upon HSV entry, host cells such as epithelial cells, macrophages, dendritic
and natural killer cells, utilize receptors called pattern recognition receptors (PRRs) to detect
invariant HSV structures, such as proteins or nucleic acids called pathogen-associated molecular
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patterns (PAMPs) [65]. In vitro and in vivo studies have demonstrated an essential role for tolllike receptor (TLR)2, TLR3, TLR5, and TLR9, in the production of type I IFN and inflammatory
cytokines during HSV infections [66-70]. Together, these studies suggest that TLR initiation of
an innate resistance to HSV infection, is possibly mediated through myeloid differentiation
factor 88 (MyD88), a downstream adaptor protein that modulate TLR signaling pathways. The
RNA helicase retinoic acid-inducible gene (RIG)-I-like receptor (RLR) has also been suggested
to function as innate immune receptors for HSV in coordination with TLR9 [66].
Recently, the cytosolic DNA sensor, STING (stimulator of interferon genes) was reported
to be essential for controlling HSV-1 infection. The authors found that STING deficient mice
were susceptible to lethal HSV-1 infection and had elevated viral loads in the brain than wild
type mice [71]. Importantly, these signs correlated with a profound defect in type I IFN
production by STING−/− mouse embryonic fibroblasts (MEFs) and bone-marrow-derived
macrophages [71]. Interestingly, in the same infection model, a very similar phenotype was
observed for GMP–AMP synthase (cGAS) knockout mice [72], suggesting that the cGASSTING pathway is critical for host defense against HSV-1.
Natural killer (NK) cells are important component of the innate immune immunity and
provide protection against different viral infections. In humans, NK cell dysfunction was
associated with severe HSV infection [73-75]. However, studies in mice have yielded conflicting
results regarding whether NK cells are important in the innate response against HSV. Studies
conducted by Habu et al., and other groups showed that depletion of NK cells with anti-NK1.1 or
anti-asialo-GM1 antibodies, increased mice susceptibility to cutaneous, intravenous, ocular, and
intravaginal challenges with HSV [76-79]. In agreement with the aforementioned studies, RagerZisman et al reported that C57BL/6 mice depleted of NK cells via cyclophosphamide treatment
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were highly susceptible to HSV infection [80]. However, the adoptive transfer of NK 1.1+ and
asialo GM-1+ cells restored resistance to HSV, while transfer of cells from NK cell-deficient
beige mice, did not [80]. In contrast, Brandt et al., in a mouse model of acute HSV-1 ocular
infection demonstrated that despite a correlation between virulence of HSV strains and their
ability to activate NK cells, infected mice developed severe ocular disease or died of encephalitis
[81]. Similarly, Bukowski and Welsh, and Wrzos et al., using depletion studies demonstrated that
NK cells were not involved in resistance to intraperitoneal HSV-1 or genital HSV-2 infections
respectively [82, 83]. The discrepancies in all these studies could be attributed to the use of
different experimental conditions including, mice type, HSV strain, or NK monoclonal
antibodies. Thus, much more work is needed in both mouse and human to fully understand the
role of NK cells in HSV infection.
Accumulating evidence in humans and mouse models of HSV shows that T cells play a
crucial role in protection against HSV infections (reviewed in [65]). HSV-2 specific cytotoxic
CD8+ T cells and CD4+ T cells heavily infiltrated the site of genital recurrences in patients, and
this was associated with viral clearance [84]. In mice, protection was severely compromised
when CD8+ T cells or CD4+ T cells were depleted [85]. Although, recent studies show that in
both CD8+ T cells depleted and CD8+ T cells deficient mice, CD4+ T cells are sufficient to clear
virus from both neural and genital sites after primary HSV-1 infection, suggesting a
compensatory role for CD4+ T cells in the absence of CD8+ T cell-mediated protection [86].
The antiviral effects of T cells during HSV infection have been demonstrated to be mediated in
an IFN-γ dependent manner [87]. For example, studies using a murine model of genital HSV-2
infection showed that IFN-γ produced by T cells and not NK cells played a role in the rapid
clearance of virus from the genital tract [88]. Furthermore, Iijima et al demonstrated that CD4+
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memory T cells IFN-γ response was initiated by MHC class II+ antigen-presenting cells
((APCs), DCs and B cells) present at the site of HSV-2 infection and resulted to limiting viral
production and spread [89]. Indeed, it is not surprising that mortality was significant in IFN-γ
receptor knock-out mice infected with HSV-1 [90]. Thus, these studies strongly suggests that the
IFN signaling pathway is important for enhancing T cell mediated responses during HSV-1 and
HSV-2 infections.
Studies have shown that γδ T cells are critical in both the innate and adaptive and
immunity against several pathogens [91]. We along with others have shown the protective role
played by γδ T cells against HSV-1 infection [92, 93]. Intramuscular vaccination of Balb/CJ
mice with the HSV-1 VC2 vaccine strain conferred protection against ocular
immunopathogenesis following ocular challenge [45]. Importantly, we observed that VC2
vaccinated mice had significant intracorneal infiltration of γδ T cells compared to compared to
mock-vaccinated animals. Conversely, when T cell migration was inhibited, VC2 vaccinated
mice succumbed to ocular challenge and exhibited significant ocular disease [45]. This suggests
that the intramuscular vaccination with VC2 altered how these cells migrate from the lymphatic
system into the infected corneas where they provide protection against HSV-1-induced ocular
pathogenesis. Furthermore, other immune correlates associated with VC2 vaccination includes
production of higher virus neutralization titers and the induction of increased the CD4+ and
CD8+ T cells with central and effector memory phenotype respectively [41].
The role of the humoral immunity in the control of HSV pathogenesis and spread is
controversial. On the one hand, it is not fully understood whether seropositivity to HSV
antibodies affect the outcome of HSV infection in humans. For example, maternal HSV
antibodies could not provide sterilizing immunity to newborns against HSV infection [94]. In a
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phase 3 trial, utilization of glycoprotein vaccines failed to confer protection against genital HSV2 infection in patients, despite the generation of high levels of neutralizing antibodies [95]. On
the other hand, experimental data from preclinical models have shown humoral responses may
contribute to disease protection. Studies conducted by Zeilin et al demonstrated that mice were
protected against HSV-2 transmission by intravaginal administration of anti-HSV antibodies
[96]. In another study, mice treated intraperitoneally with gD-specific antibody, had reduced
viral loads in the vaginal epithelium and were significantly protected against HSV-2 clinical
disease [97]. Similarly, in the guinea pig model, antibody treatment resulted in reduced infection
of the genital mucosal and dorsal root ganglia [98]. In addition, the rates of subsequent
spontaneous recurrent disease in antibody-treated animals was also significantly reduced,
provided that antibody is delivered in high quantities during the first 24 hours of HSV-2
infection [98]. Despite these findings in preclinical models, a lack of clinical verification in
humans warrants further work in order to fully understand the role of humoral responses in
controlling HSV infections and associated clinical symptoms.

1.6. Introduction to oncolytic virotherapy
Apart from cancer cells, the tumor mass is comprised of a number of cellular and
subcellular constituents. These include resident stromal cells, such as fibroblast and endothelial
cells, immune cells as well as cancer-associated fibroblasts (CAFs) and extracellular matrix
(ECM) proteins, collectively known as the tumor microenvironment (TME) [99]. Interactions
between cancer cells and the components of the TME creates an immunosuppressive network,
which profoundly influences tumor development, progression, and metastasis [100]. Importantly,
immunosuppression in the TME may result in a deficient therapeutic response and resistance to
treatment.
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Due to the prominent role of the TME in cancer, much effort has been put into developing
therapies that target components of the TME. A notable example is the clinical success of
immune checkpoint inhibitors (ICIs), which function to restore anti-tumor T-cell activity [101].
Although current cancer immunotherapies including ICIs and chimeric antigen receptor T cells
(CAR-T) have demonstrated promising therapeutic outcomes, limitations such as low response
rate and serious side effects have been reported in some cancer patients [101, 102].
Oncolytic virotherapy (OVT) represents a novel form of immunotherapy, where oncolytic
viruses (OVs) are used to kill cancer cells. The lytic activity of the virus promotes release of
tumor antigens and provides an immunogenic context that is thought to support the development
of anti-tumor immune responses [103-105]. Additionally, as a combination therapy, OVT has
also been shown to improve the efficacy of other immunotherapies, such as ICIs [106]. Many
virus families are currently studied as oncolytic virotherapies [107]. Each has characteristics that
inform their utility. Due to the extensive clinical development of herpes simplex viruses as OVT,
including the only FDA approved OVT, we focus this part of the dissertation primarily on
oncolytic HSV-1 (oHSV) OVT.
HSV-1 possess several advantages over other viruses that inform their use as OVT agents.
These include: (a) its ability to infect a variety of cell types, (b) its large genome (152 kb) that
allows for insertion of large or multiple transgenes, (c) it remains as an episome upon infection,
precluding insertional mutagenesis, (d) it can be controlled by antiviral drugs and (e) the
extensive knowledge of the molecular biology of herpesvirus infection [108].
In this part of this chapter, we discuss what is known regarding how oncolytic HSV affects
the tumor microenvironment to promote anti-tumor immune responses and how this knowledge
may be used to inform the rational design of future, more efficacious immunotherapies.
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1.7. Herpes simplex virus type 1-derived oncolytic viruses
The concept of using viruses for cancer treatment was conceived following observations in
case reports that tumor regressions were sometimes associated with natural virus infections
[109]. These anecdotal observations spawned a small number of clinical studies. A notable
example was the study conducted in 1949, where 22 patients suffering from Hodgkin’s disease
were treated with sera or tissue extracts containing hepatitis virus [110]. From 1950 to 1970,
more studies were performed where cancer patients were administered wild type viruses,
including Egypt 101 virus, adenovirus, and mumps virus [109]. Although there were often
glimmers of activity in these studies, these viruses were not deemed viable cancer therapeutics.
This was largely due to safety concerns and because of the limited understanding of the
molecular biology of these viruses. As a result, there was a decrease in activity in the field of
OVT until the emergence of recombinant DNA technology in the early 1990s [109]. This
technology facilitated the development of safer OVT by allowing targeted mutations to improve
the safety profiles of a number of viruses.
At the forefront of these studies, work with HSV-1 heralded the era of engineering viruses
to selectively replicate in malignant cells, when Martuza et al. demonstrated first that an HSV-1
mutant, dlsptk, which lacks the viral gene encoding thymidine kinase (TK), efficiently killed
both immortalized and short-term human malignant glioma cells in vitro [111]. Their
experiments in nude mice with engrafted subcutaneous or intracranial glioma, also revealed that
the intratumoral inoculation of dlsptk caused tumor growth inhibition and prolonged survival
[111]. Importantly, the oncolytic herpes simplex virus (oHSV) dlsptk served as a proof of
principle that attenuated mutants of HSV-1 could potentially be used for cancer therapy.
However, while the deletion of thymidine kinase in the dlsptk virus allows it to selectively
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replicate in tumor cells, this virus is also not susceptible to conventional anti-herpesvirus drugs
such as acyclovir [112]. Thus, other rationally designed HSV-1-derived viruses have been
developed.
At present, Talimogene laherparepvec (T-VEC; Imlygic™), a mutated HSV-1 vector of the
JS-1 strain with deletions in the infected cell protein (ICP) γ34.5 and ICP47 genes, is the only
OVT approved by the United States Food and Drug Administration (FDA) and European Union
(EU) for the treatment of human melanoma cancers [113, 114]. TVEC™ and other oHSV will be
described in more detail below. While, at present, TVEC™ is the only FDA approved OVT,
there are a number of HSV-1-derived oncolytic viruses being studied in pre-clinical and clinical
settings. These viruses use different attenuation and delivery strategies as well as possess a
number of transgene insertions many of which are expected to alter their interactions with the
TME.
1.8. Tumor microenvironment
The TME represents an important barrier that can hinder immune responses against tumors
and also attenuate immunotherapeutic efficacy (Figure 1.3). In situ immune components of
tumors, including T cells, B cells, natural killer cells (NK), dendritic cells (DCs), macrophages,
granulocytes as well as suppressive regulatory cells subtypes such as regulatory T cells (Tregs),
regulatory B cells (Bregs), and myeloid-derived suppressor cells (MDSCs), play crucial roles in
the host cancer immunosurveillance system, although their contribution varies between tumor
types and among patients with the same cancer [115]. The type, density, and location of immune
infiltrates within a tumor have been suggested to have a clinical prognostic impact [116].
Importantly, the infiltration of T cells, particularly CD8+ T cells, have has been shown to
correlate with augmented responses to immunotherapy and improved survival [117-119].
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Figure 1.3. The tumor microenvironment (TME). Major cellular constituents of the TME during
oncolytic virotherapy (OVT).
Tumors can be classified as immunologically “hot” or “cold” [118, 120]. “Hot” or inflamed
tumors have an abundance of infiltrating T cells and molecular signatures of immune activation
and are usually responsive to immunotherapy [115]. By contrast, “cold” tumors are defined to
have limited number of infiltrating T cells and are not sufficiently primed for immune
recognition [115]. These cold tumors often contain Tregs, Bregs, and MDSCs, which prevent
cytotoxic immune cells from penetrating into the TME [115]. Therefore, turning a cold tumor hot
is essential and may significantly enhance the therapeutic efficacy of cancer immunotherapies.
Unfortunately, only a minority of patients with hot cancers seem to respond and benefit from
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immunotherapies like checkpoint blockers, cancer vaccines and CAR-T cells. To improve
clinical outcomes in patients with a variety of cancer types, significant efforts are currently
undertaken to combine immunotherapies themselves or with traditional cancer therapies, such as
chemotherapy, radiation therapy, or surgery [118].
The generation of an anti-tumor response involves a cyclic process referred to as the
cancer-immunity cycle [121]. This cycle begins with liberation of neoantigens generated as a
result of spontaneous immunogenic cell death, chemotherapy, radiation, and/or OVT among
others. The released neoantigens are captured and processed by antigen-presenting cells (APCs),
which migrate to the draining lymph nodes to prime and activate tumor-specific T cells. Tumorspecific T cells traffic to and infiltrate the tumor bed where they recognize and kill cancer cells.
The killing of cancer cells releases additional tumor antigens, fueling the cancer immunity cycle.
1.9. Tumor microenvironment and oncolytic virotherapy
1.9.1. OHSV and Anti-Tumor Immune Responses
A number of candidate oHSVs are currently in development [122]. Our group and others
have demonstrated the significant impact of oHSV OVT on the development of anti-tumor
immune responses in pre-clinical or clinical studies [123-126]. Specifically, these studies have
highlighted the ability of oHSVs to change the TME from “cold” or immunosuppressive to “hot”
or immunostimulatory as a component of their efficacy. Given the central role of the TME in
controlling the development of anti-tumor immune responses, understanding the cellular and
molecular changes in the TME during OVT would inform the development of more efficacious
immunotherapies for the treatment of human and animal cancers. While the pre-clinical pipeline
of oHSV is rich with promising candidates [48, 123-126], we focus in this section on several
oHSVs for which there is clinical data.
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T-VEC™ is the first FDA approved OVT for treatment of patients with unresectable
melanoma [113]. T-VEC is a modified HSV-1 OV derived from the JS-1 strain in which two
copies of its ICP34.5 genes which encodes the neurovirulence factor are deleted [114]. The
ICP34.5 gene is also important for viral replication, viral egress from cells and prevention of
cellular block to viral protein synthesis in infected cells through its inhibitory activity on the
protein kinase R (PKR) pathway [127-129]. PKR stops protein synthesis by phosphorylating the
eukaryotic translation initiation factor 2 alpha (eIF2α) [129]. The ICP34.5 protein redirects
protein phosphatase 1α (PP1α), which reverses the phosphorylation of eIF2α to restore protein
synthesis [129]. Deletion of the ICP34.5 gene decreases pathogenesis and prevents replication of
the virus in normal cells. In addition, T-VEC contains a deletion in the gene encoding the ICP47
protein [114]. HSV-1 uses the ICP47 protein to inhibit transporter associated with antigen
presentation (TAP), thus it downregulates antigen presentation through MHC Class I, as a way of
evading immune response during infection [130]. The deletion of the ICP47 gene increases
antigen presentation and enhances viral immunogenicity. Additionally, ICP47 inactivation in TVEC puts the herpes unique short 11 (US11) under immediate early promoter control which
results in enhanced and earlier expression of US11, whose gene product inhibits PKR activity
[131]. Finally, two copies of the human granulocyte–macrophage colony stimulating factor
(GM-CSF) gene are inserted in place of the deleted ICP34.5 gene loci [114]. GM-CSF functions
as a potent immune stimulator by promoting the recruitment and maturation of DCs and
macrophages [114]. It is not clear what contribution the GM-CSF makes to anti-tumor efficacy
of T-VEC™ as other vectors have shown efficacy in the absence of cytokine transgenes [123].
T-VEC demonstrated strong lytic activity when tested in vitro in human tumor cell lines,
including melanoma and pancreatic cancer cells [114]. In mice, intratumoral injection of A20
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lymphoma tumors with T-VEC resulted in significant reduction of tumor volume of both injected
and non-injected tumors, and treated mice rejected subsequent tumor re-challenge [114].
Corroborating the aforementioned study, a recent study in mice found similar systemic immune
responses induced by T-VEC to distal untreated tumors [132]. Furthermore, a significant
increase of CD3+ and CD8+ T cells was observed in both injected and contralateral tumors and
these T cells were tumor specific [132]. In humans, TVEC monotherapy has also demonstrated
distant responses in untreated tumors [133]. Intralesional injection of T-VEC altered the TME
and increased MART-1 (melanoma antigen recognized by T-cells 1) specific CD8+ T-cell
infiltration in melanoma patients [133]. There was also evidence of these cytotoxic T cells in the
peripheral blood of treated patients, suggesting the induction of systemic anti-tumor immunity
[106, 133]. In addition, injected lesions demonstrated a decrease in Tregs, T-suppressor cells,
and MDSCs [121]. In another study, T-VEC in combination with anti-PD-1 antibody,
pembrolizumab, altered the TME and increased cytotoxic CD8+ T cell infiltration [94]. These
findings demonstrate that OVT can improve the efficacy of ICIs as a combination therapy.
The G207 strain is an attenuated HSV-1 OV based on the HSV-1 (F) strain, which contains
deletions of both copies of the ICP34.5 gene, as well as an Escherichia coli lacZ gene insertion
which inactivates the ICP6 gene [134]. The ICP6 gene encodes for a subunit of ribonucleotide
reductase, an enzyme necessary for viral DNA synthesis in quiescent cells [135]. The
inactivation of the ICP6 gene restricts the virus to replicate in actively dividing cells, thus giving
the virus selectivity for tumor cells [134].
Early reports demonstrated the utility of G207 as an in situ cancer vaccine [136]. In this
study, G207, after intratumoral inoculation of colorectal carcinoma cells, was reported to induce
an anti-tumor immune response. Further, in mice that had two tumors engrafted, intratumoral
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inoculation with G207 reduced tumor growth rates in treated and contralaterally engrafted but
untreated tumors, demonstrating an abscopal effect [136]. Intratumoral inoculation with G207 in
pre-clinical models of U-87MG gliomas resulted in a significant reduction of tumor volume and
prolonged survival [134]. Tumor vasculatures were destroyed in mice bearing
rhabdomyosarcoma xenografts following intratumoral treatment with G207 [137]. In the same
line, work by Huszthy et al. in athymic nude rats implanted with human glioblastoma (GBM)
biopsies further suggests that G207 may possess antiangiogenic properties [138]. The authors
also observed accumulated CD68+ microglia cells and macrophages within the tumor bed around
viral plaques in G207 injected tumors [138]. In this study, viral plaques and CD68+ cells within
the tumor tissue were confirmed by immunostaining [138].
In a Phase 1b clinical trials with patients suffering from recurrent GBM, G207 was
introduced directly into resected cavities after tumors were removed surgically [139]. G207
demonstrated high safety profiles with post treatment evidence of significant infiltration of CD8+
T cells and macrophages/microglia into the TME [139]. Most recently, results from the first inhuman trial of G207 for malignant pediatric cerebellar brain tumors were reported [140, 141].
Patients had catheters introduced which allowed direct administration of virus to tumors. Results
were highly encouraging with only a single non-responder of 12 patients enrolled. There was
substantial evidence of lymphocyte infiltration into tumors in some patients [141]. Interestingly,
when patients who were HSV-1 seropositive were excluded from analysis, increased circulating
numbers of natural killer (NK) cells was found to positively correlate with survival. Median
survival for front-line therapies of high-grade pediatric gliomas is 5.6 months [142, 143]. While
not directly comparable, in this trial, G207 treatment resulted in median survival of 12.2 months
[121]. Moreover, at the time of reporting four of the patients were still surviving 18 months after
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treatment with G207. This result exceeded expectations and provides strong support for Phase 2
trials.
HSV1716 is derived from HSV-1 strain 17 and lacks both copies of the ICP34.5 genes
[144]. HSV1716 OVT has been demonstrated to reduce tumor growth and provide survival
advantage as well as to induce significant tumor infiltration of inflammatory immune cells,
including CD4+ T cells, CD8+ T cells, NK cells and macrophages in mouse models of
intracranial M-3 S91 Cloudman melanoma, 4T1 breast, and rhabdomyosarcoma cancers [145147]. One mechanism used by HSV1716 to recruit effector immune cells into the TME is
through the upregulation of chemokines: IFN-γ-inducible protein-10 (IP-10 also known as
CXCL10) and monokine induced by IFN-γ (MIG also known as CXCL9) [148]. IP-10 and MIG
are known to have chemotactic effects on activated T cells and NK cells. Recent studies in
PyMT-TS1 breast cancer model further demonstrated HSV1716’s ability to alter the TME
immunosuppressive milieu. In this study, HSV1716 OVT resulted to reduced number of Tregs
and reprogrammed M2-like TAMs to a more pro-inflammatory M1-like phenotype in the TME
when compared to matched controls [149].
HSV1716 has been evaluated in a number of clinical trials as an intervention strategy for
melanoma, mesothelioma, non-CNS solid tumors, and glioma [150-153]. For mesothelioma,
patients were administered HSV1716 via an intrapleural catheter [153]. In the majority of
patients after treatment with HSV1716, levels of Th1 cytokines IL-2, IFN-g, TNFa in pleural
fluid were increased 5–10-fold [153]. Interestingly, the authors reported the development of
novel anti-tumoral antibody responses in four of the patients treated with HSV1716 [56]. In a
previous study, HSV1716 was administered intravenously in young patients with extra-cranial
solid tumors [151]. Impressively, intravenous administration at up to 107 infectious doses was
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well tolerated and two patients exhibited stable disease. Unfortunately, TMEs were not studied in
biopsied specimens. In another study in young patients with brain tumors, up to 107 infectious
unitsPFU were administered intratumorally [151]. Administration was well tolerated. No
biopsies were performed, but imaging revealed metabolic activity consistent with inflammatory
responses.
HF10 is a non-engineered, spontaneously mutated OV derived from the HSV-1 HF strain.
At the genome level, HF10 lacks the expression of functional unique long (UL) 43, UL49.5,
UL55, UL56, and latency-associated transcripts (LAT), and overexpresses UL53 and UL54
genes [154]. The functions of these altered genes and how they may contribute to the antitumor
efficacy of HF10 have been reviewed [154]. In a C3H mouse model of head and neck squamous
cell carcinoma (SCC VII), intratumoral injection of HF10 reduced tumor growth and
significantly enhanced survival [155]. Immunohistochemistry analysis showed evidence of tumor
necrosis and infiltration of CD8+ T cells around HSV-infected cells in HF10 treated tumors [58].
These findings correspond with the results of previous studies of HF10 OVT against other
malignancies [156], however, the authors did not show whether HF10 as a monotherapy, altered
the immunosuppressive cell populations in the TME.
There have been several clinical trials to evaluate the safety and efficacy of HF10 for a
number of different cancers including head and neck squamous cell carcinoma (HNSCC), breast
cancer, melanoma and pancreatic cancer [154, 157-161]. All trials reported that HF10 was safe
and tolerable in each trial. Analysis of infiltrating immune cells was reported in a subset of these
trials. In a recent Phase I trial of nonresectable pancreatic cancer where patients were treated
intratumorally with HF10, immunohistochemistry on HF10 treated tumors revealed a statistically
significant infiltration of CD8+ T-cells compared to tumors that did not receive HF10 [161].
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Analysis of CD4+ T-cells revealed no statistically significant differences between treated and
untreated tumors. The study also included analysis of macrophages and other APCs. Of these,
macrophages were found to infiltrate tumors in statistically significant numbers in HF10 treated
tumors relative to untreated tumors. Consistent with a trial for G207 [141], the authors noted an
increase in circulating NK cells in patients treated with HF10.
NV1020 is derived from the HSV-1 strain F designated as R7020, that was originally
developed as a vaccine against HSV-1 and HSV-2 infection [162]. The NV1020 genome
contains a 15-kb deletion region at the UL/S junction, which encompasses genes encoding ICP0,
ICP4, and ICP34.5, as well as UL56 [163]. NV1020 is further attenuated by a 700-bp deletion in
the tk gene locus that prevents the expression of the overlapping UL24 gene [163]. In addition,
the virus carries an insertion of an exogenous copy of the HSV-1 tk gene, and a 5.2-kb fragment
of HSV-2 DNA [163]. NV1020 replicates efficiently in transformed cells and the insertion of the
tk gene ensures that viral infection or toxicity can be controlled with antiviral drugs, like
acyclovir.
The safety and efficacy profile of NV1020 in the treatment of peritoneally disseminated
gastric cancer has previously been investigated in preclinical models. When tumor bearing mice
were treated intraperitoneally with NV1020, it significantly reduced tumor burdens and
conferred significant survival advantage when compared to control treated animals [164]. In
addition, when the brain, liver, kidneys and tumor of NV1020 treated mice were evaluated for
HSV biodistribution and necrosis, immunohistochemistry analysis showed no virus or necrosis in
any non-tumor tissues [164]. However, significant HSV staining and extensive necrosis was
observed in tumor specimens. Furthermore, NV1020 has also been shown to have significant
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promise in the treatment of other pre-clinical cancer models, including pancreatic, pleural, and
bladder cancer, as well as head and neck squamous cell carcinoma [165-168].
The safety and tolerability of NV1020 was first evaluated in a Phase 1 study involving
patients with colorectal cancer metastatic to liver (mCRC) [169]. NV1020 was administered to
12 patients (3 per cohort) via intrahepatic arterial infusion in escalating dose of 3 × 106, 1 × 107,
3 × 107, and 1 × 108 PFU. All patients received cycles of floxuridine through a chemotherapy
infusion pump with several combinations of chemotherapy (irinotecan, 5-fluorouracil,
leucovorin, or oxaliplatin) 1 and 2 months after administration of virus. Most frequent adverse
events associated with the administration of NV1020 included pyrexia, headache and rigor.
Although, one patient had a severe case of increased gamma glutamyl transferase (GGT) levels
occurring 12 h after virus infusion. No significant change in serum levels of cytokines and T
cells due NV1020 administration was observed. Radiologic assessment of anti-tumor activity 28
days after viral administration showed that two patients had reduction in tumor size of 39% (1 ×
108 PFU cohort) and 20% (3 × 107 PFU cohort), respectively. In addition, 3 patients
demonstrated progression of disease, while 7 patients had disease stabilization.
A subsequent study aimed to evaluate the therapeutic effects of an optimally tolerated dose
of NV1020 in patients with mCRC has been completed. According to the results, treatment with
virus through hepatic artery infusion was well tolerated and was associated with stable disease in
50% of the patients. Immunologically, individual infusions of NV1020 induced a dose-related
increase in the levels of IL-6, TNF-α, and IFN-γ. The addition of chemotherapy resulted to a
median time to progression (TTP) and a median overall survival (OS) of 6.4 months and 11.8
months respectively. Altogether, this study suggests that NV1020 can stabilize liver metastases
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and sensitize tumors to chemotherapy resulting prolonged overall survival in patients with
mCRC [170].
OncSyn is a fusogenic oHSV derived from the wild type HSV-1 (F) strain. Like NV1020,
OncSyn contains genomic deletions in its UL56 gene, and one of the two copies of the α0, γ34.5,
gene, and the α4 gene [171]. In addition to these modifications, the region of OncSyn latency
associated transcript (LAT) is mutated. To further increase the ability of the OncSyn virus to cause
virus-induced cell fusion, a single amino acid change (gBsyn3 mutation) was introduced in the
virus gB protein [172]. In addition to producing larger syncytial plaques, this modification
increased the virus replication [171]
Using a xenograft model of human breast cancer (MDA-MB-435S-luc (MM4L)) in mice,
our laboratory demonstrated that the oHSV OncSyn is safe and possess anti-tumor potentials. We
showed that intratumoral delivery of the virus resulted in decreased tumor growth rate and size
[171]. Histopathological analysis of tumor specimen showed evidence of extensive necrosis in
tumors treated with OncSyn compared to tumors treated with PBS.
1.9.2 Interactions of oHSV with the tumor vasculature
Tumor vasculatures restrain the migration of immune cells from reaching tumor targets
through the expression of immunosuppressive ligands and the downregulation of adhesion
molecules [173]. Studies on how oHSV-derived OVT disrupts tumor-induced vasculature has
demonstrated mixed results. On one hand, studies have shown a direct anti-angiogenic effect of
oHSV [174]. Although most of the reported anti-angiogenic oHSV vectors are armed with
angiostatic factors or angiogenesis inhibitors. One example is the oHSV RAMBO (rapid
antiangiogenesis mediated by oncolytic virus). Hardcastle et al. hypothesized that incorporating
an extracellular fragment of the brain-specific angiogenesis inhibitor 1 (BAI1), vasculostatin
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(Vstat120), in RAMBO would counter the downregulation of thrombospondin 1 (TSP-1) and the
increased cysteine-rich 61 (CYR61) integrin activation in the TME, thereby enhancing the antitumor efficacy [175]. Indeed, RAMBO treatment promoted significant anti-tumor and antiangiogenic responses over the control virus, in the treatment of mice bearing intracranial and
subcutaneous gliomas. In addition, RAMBO-treated tumors showed a significant reduction in
tumor microvessel density (MVD) and vascular volume fraction (VVF) [175]. Similarly, Tsuji et
al. demonstrated that treatment with T-TSP-1, an oHSV armed with human TSP-1, reduced
tumor MVD and exerted an enhanced anti-tumor efficacy against human gastric cancer in vivo
[176]. On the other hand, other reports have suggested that oHSVs induce pro-angiogenic

responses [177, 178]. The downregulation of TSP-1, an anti-angiogenic factor, and the increased
expression of CYR61, a pro-angiogenic factor, in infected cells are some of the limitations of the
neovascular responses associated with oHSV infection [163, 164]. When taken together, there is
no clear census regarding the anti-angiogenic or pro-angiogenic nature of oHSV vectors.
1.9.3. Interactions of oHSV with the extracellular matrix of tumors
The extracellular matrix (ECM) of tumors controls a number of important regulatory
processes central to tumor pathology [179]. However, its function as a barrier to prevent viral
replication and spread has motivated a number of groups to manipulate the ECM as a component
of OVT [180-185]. These efforts include the exogenous addition of enzymes to degrade the
ECM during OVT and the engineering of novel viruses that express matrix degrading enzymes.
The molecular makeup of the ECM can be unique to each tumor. As such, the approaches to
disrupt the ECM as a component of OVT may not represent a “one size fits all” solution. Further,
ECM remodeling proteins such as matrix metalloproteinases (MMPs), while generally
understood to be protumoral, can have anti-tumoral effects depending on individual tumor
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characteristics [186]. Bearing this in mind, a number of groups have been successful
incorporating ECM-targeting approaches for OVT.
Building on earlier work that demonstrated exogenous addition of matrix metalloproteinase
9 (MMP9) in neuroblastoma cells enhanced oHSV spread [180], Sette et al. created a novel
oHSV that expresses MMP9 (KMMP9) [187]. MMP9 degrades Type IV collagen which is
present in the ECM of glioblastoma multiforme (GBM). KMMP9 possessed enhanced spread in
GBM spheroids and treatment of intracranial mouse xenografts with KMMP9 resulted in
increased survival compared to xenografts treated with control non-MMP9 expressing-virus
[187].
Mckee et al. demonstrated that targeting collagen using bacterial collagenases enhanced
efficacy of OVT in melanoma xenograft models [183]. Bacterial collagenases were introduced
intratumorally, coincident with MGH2, an oHSV vector. The combined effect was enhanced
intratumoral spread of virus and significantly reduced tumor growth rates.
In brain tumors many CSPGs are upregulated and this upregulation is associated with the
enhanced pathogenicity of these tumors. Sugar modifications on CSPGs are responsible for
limiting diffusion in the ECM. Dmitrievea et al. reasoned that removal of these moieties with a
bacterial enzyme, chondroitinase ABC (chase-ABC), would facilitate replication and spread of
oHSV through CNS tumors [182]. To this end, they engineered an oHSV (OV-Chase) to express
Chase-ABC. OV-Chase significantly enhanced replication and spread through subcutaneous
gliomas, reduced tumor growth rates and increased survival in mouse glioma xenografts.
More direct approaches have been taken to subvert the ECM barrier to viral replication and
spread through tumors. E-cadherin is a molecule that facilitates cellular adhesion through nectin1. Nectin-1 is the predominant receptor for HSV-1 infection and the addition of E-cadherin was
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hypothesized to directly increase viral infection and spread by promoting receptor binding [181].
This group engineered an oHSV (OVCDH1) to express human E-cadherin. OVCDH1 exhibited
enhanced spread through GBM cells in vitro, reduced tumor growth rates in vivo and enhanced
survival in xenograft and immunocompetent models of GBM.
Most studies of the effect of manipulating the ECM on OVT efficacy have focused on viral
replication and spread. There has been relatively little effort spent to look at the effect
manipulating the ECM during OVT has on immune cell infiltration. The above study is
particularly interesting in this respect, as they examined the effect of E-cadherin on infiltrating
NK cells, macrophage, microglia and T-cells. Perhaps due to an increase in cytolytic activity of
OVCDH1 this group noted an increase in NK cell infiltration into tumors after OVCDH1
treatment versus control virus treatment. No other differences in immune cell infiltration were
observed between OVCDH1 and control groups.
Finally, while the above groups demonstrated that overexpression of ECM proteins can
benefit OVT efficacy, Mahller et al., reasoned that inhibition of ECM protein activity may
benefit OVT [184]. This group hypothesized that, as the function of many ECM protein activities
are pro-tumoral, using a virus to express TIMP-3, a matrix metalloprotein inhibitor, might
benefit oHSV-derived OVT. TIMP-3, tissue inhibitor of MMPs 3, is an inhibitor of all MMPs.
Treatment with TIMP-3 reduced tumor growth rates in a number of cancer models [188-190].
Using this rationale, Mahller et al., engineered the G207 oHSV (described below and in Table
1.2) to express TIMP-3 and called it rQT3. Compared to control virus which expresses
luciferase, treatment of neuroblastoma and malignant peripheral nerve sheath (MPNST)
xenografts with rQT3 was superior at reducing tumor growth rates and enhancing survival.
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Table 1.2. Summary of HSV-derived oncolytic viruses discussed
Oncolytic Herpes
Simplex Virus
KMMP9

Strain

HSV Gene Mutations Transgene

Reference

KOS

[187]

rQT3
MGH2

F
F

Deletion of residues
2–24 and amino acid
substitution,
Y38C, in gD. gB:NT
ICP34.5Δ, ICP6Δ
ICP34.5Δ, ICP6Δ

OVCDH1

Q1

ICP34.5Δ, ICP6Δ

OV-Chase

F

ICP34.5Δ, ICP6Δ

T-VEC

JS-1

ICP34.5Δ, ICP47Δ

G207

F

ICP34.5Δ

HSV1716

17

HF10

HF

NV1020

F

OncSyn

F

G47Δ-mIL-12

F

VC2

F

ICP34.5Δ
Reduced expression of
UL43, UL49.5, UL55,
UL56 and LAT genes;
increased expression
of UL53, and UL54
genes
Joint deletion (1 copy
of ICP0,
ICP4, ICP 34.5),
UL56Δ, UL5/6
duplication, UL24Δ,
TK Δ
α0 Δ, γ34.5 Δ, α4Δ,
LAT region, gBsyn3
mutation
ICP34.5Δ, ICP6Δ,
ICP47Δ
gKΔ, UL20Δ

RAMBO

F

ICP34.5Δ, ICP6Δ

T-TSP1

F

ICP34.5Δ, ICP6Δ,
ICP47Δ
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Human EGFR,
miR-124 target
in ICP4 3′UTR,
MMP9
Human TIMP3
CYP2B1 and
human shiCE
Human CDH1
Bacterial
Choindroitinase
ABC
Human GMCSF
Escherichia
coli lacZ gene
at ICP6
None

[191]
[192, 193]
[181]
[182]
[114]
[134]
[144]
[154]

None

TK under ICP4
promoter
control, 5.2-kb
fragment
of HSV-2 DNA

[163]

[171]
None
Mouse IL-12
None
Human
Vstat120
Human TSP-1

[194]
[123]
[175]
[176]

1.10. OHSV and immune checkpoint inhibitors (ICI)
A major mechanism through which the TME creates a hostile environment for immune
cells is by inducing the upregulation of surface inhibitory receptors such as cytotoxic Tlymphocyte-associate protein 4 (CTLA-4), and programmed death-1 (PD-1), as a mechanism for
tumors to avoid immune surveillance. CTLA-4 blocks T cell activation, by counteracting CD28mediated costimulatory signaling, by binding to B7 ligands expressed on APCs [195]. CTLA-4
is also constitutively expressed on Tregs, which contributes to the immunosuppression of the
TME [101]. PD-1 is expressed on activated T cells and binds to one of two ligands, program
death-ligand 1 (PD-L1) and PD-L2. Numerous tumors express PD-L1, which when bound to PD1, attenuates T cell functions such as proliferation, cytokine production, and cytotoxicity [196,
197]. Lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin domain and mucin
domain-3 (TIM-3), and T cell immunoglobulin and ITIM domain (TIGIT) are other immune
checkpoints known to inhibit effector T cell responses [198].
The blockade of the PD-1/PD-L1 and/or CTLA-4/B7 inhibitory pathways by ICIs can
reinvigorate the effector functions of T cells in the TME. However, limited response rates and
treatment related toxicities has been reported with ICIs [101, 199]. Heterogenicity between
cancer types, and the lack of sufficient immune activation are some of the reasons for low
response rates. Thus, it is reasonable that the outcome of ICI therapeutic intervention can be
improved as a combinatory therapy with other treatment modalities such as OVT. In this sense,
OVs not only lyse the tumors cells but also alters the TME into a highly immunogenic one,
which has been suggested to favor the efficacy of immune checkpoint blockades. For example, in
a syngeneic murine rhabdomyosarcoma model, combining oHSV HSV1716 with PD-1 blockade
significantly prolonged survival compared to PD-1 blockade or HSV1716 treatments alone
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[147]. In addition, the therapeutic outcomes of the combinatory therapy correlated with increased
tumor infiltration of CD4+ and CD8+ T cells, but not Tregs, compared to the control groups
[147]. Similarly, when Saha et al. tested a triple combination of anti-PD1, and anti-CTLA4
antibodies with an oHSV expressing murine IL-12 (G47∆-mIL-12) in mouse GBM models, they
observed that the treatment produced durable cures in most mice [200]. The dual combination of
anti-CTLA4, and anti-PD1 increased median survival by 37% compared to 20% observed for
anti-CTLA-4 alone. However, the addition of G47Δ-mIL12, with anti-CTLA4, and anti-PD1 led
to 89% long-term survivors. Analysis of tumor-associated immune cell infiltrates showed that
the treatment led to reduction of Tregs, influx of M1-like macrophages, increased infiltration of
CD8+ T cells, and increased T effector to T regulatory cell ratios. Furthermore, when
macrophage, CD4, or CD8+ T cells were depleted, the efficacy of the treatment was impaired,
suggesting that are they are required for efficacy [200].
Concordant with these findings in murine studies, the importance of combining ICIs with
oHSV-derived OVT in clinical settings has also been demonstrated. In a Phase 1b clinical trial
with patients with advanced melanoma, anti-PD-1antibody (pembrolizumab) plus T-VEC
combination led to an increased tumor infiltration of IFN-γ+ CD8+ T cells in patients with
tumors with low level of immune cell infiltrates and negative IFN-γ signatures [106]. This
combination therapy resulted in a high objective response rate (ORR) of 62% (with a 33%
complete response) compared with prior single agent pembrolizumab therapy. Data from another
clinical study which tested the combination of CTLA-4 blockade (ipilimumab) with T-VEC in
melanoma patients, showed that the combination was well tolerated and had greater anti-tumor
efficacy than ipilimumab monotherapy [201]. According to the results, the ORR was
significantly higher for the combination therapy than for ipilimumab alone (39% versus 18%,
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respectively, p = 0.002). Taken together, these promising pre-clinical and clinical results suggest
that OVT can sensitize immunologically cold tumors to ICIs.

1.11. Conclusions
Numerous studies carried out by several groups have unraveled the promising potential of
HSV for oncolytic immunotherapy. With advances in genetic engineering technology enabling
the rapid generation of new recombinant HSVs, the detailed understanding of how HSV interacts
with host cells can be exploited in different ways to produce HSV vectors with therapeutic
capabilities including HSV-1 vectored vaccines and cancer immunotherapies.
Studies have shown that “hot” or inflamed tumors, which contain an abundance of
infiltrating T cells in the TME, are more likely to respond to immunotherapies, as compared with
“cold” immune desert tumors, which have low or no T cells [115]. Thus, strategies to turn “cold”
tumors “hot” and hence promote anti-tumor immunity hold great promise. One such promising
strategy includes OVT, a novel form of cancer immunotherapy.
Despite the FDA approval of T-VEC and the promising results yielded by other oHSVs in
clinical trials, there are still many obstacles that needs to be resolved for the further development
of improved HSV-1 OVTs. The first challenge is choosing an optimal OVT, as a single OV may
not be effective in all types of cancers. Many HSV-1 OVs are engineered to replicate in actively
dividing cells because it has been proposed that cancer cells are actively replicating while
healthy cells are not. Unfortunately, not all cancer cells within a tumor mass undergo active
replication [202]. In addition, the TME contains non-tumoral cells such as immune infiltrates,
fibroblast, and endothelial cells, which have been shown to not support the replication of OVs
designed according to the aforementioned principles [203, 204]. More recent approaches to
restrict HSV-1 OVs to cancer cells include receptor retargeting [205], use of specific promoters
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to express critical viral genes [206], transcriptional and translational regulation of essential viral
gene expression [207], and incorporation of miRNA target sites into viral genes [208]. However,
all of these approaches possess limitations, including the possibility of reversion of attenuation,
increased toxicity, in addition to over-attenuation of viral replication and thus efficacy. Hence, an
attractive approach for the development of next generation HSV-1 OVTs might focus on
maintaining much of viral replication potential, while eliminating their ability to spread to the
nervous system, where they can establish latency, possibly recombine with wild-type virus
strains, or reactivate and subsequently cause disease. Our laboratory has recently identified
mutations that blocks HSV-1 entry into neurons [32]. This novel oHSV, VC2, replicates to
similar viral titers to its parental HSV-1 (F) strain virus, but is not neuroinvasive, and in the
B16F10-derived mouse melanoma model, demonstrated significant efficacy and altered the
immunosuppressive TME [123].
Optimizing efficient HSV-1 OV delivery systems is another challenge that requires further
studies. Intratumoral delivery is the most common route of oHSV delivery in many pre-clinical
and clinical studies. This method directly targets the OV into the injected tumor and bypasses
viral dilution in blood, antiviral immunity or sequestration in non-targeted cells or tissues.
Intratumoral delivery is suitable for cutaneous or subcutaneous lesions treatment, although safety
issues can arise for deep visceral lesions or those located in the brain, especially when repeated
dosing is needed [209]. Utilization of image-guidance techniques may be a promising approach
to maximize oHSV delivery to remote inaccessible lesions [210]. On the other hand, intravenous
delivery represents an ideal route of OV administration as it enables broad virus distribution to
both primary and metastatic tumors regardless of location. In addition, this route is relatively
noninvasive, and inoculations can be frequently repeated [202]. However, for HSV-1 OVs, pre-
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existing immunity is a concern as the virus may be rapidly cleared by pre-existing circulating
neutralizing antibodies before it reaches its target tissues. Studies from our laboratory and other
groups have demonstrated that prior immunity to HSV-1 does not have an effect on the efficacy
of HSV-1 OVT in mice [114, 123] or humans [113], although others have reported that it did
enhanced therapeutic outcome in vivo [145]. It has been suggested that the latter may be true,
particularly for herpesviruses, which as part of their replication strategy periodically reactivate
and spread, causing continued activation of robust adaptive immune responses [211]. Therefore,
rather than suppressing HSV-1 derived OVTs, pre-existing immunity may enhance their efficacy
[211]. However, more studies are needed as there are limited efficacy data from intravenous
oHSV trials to judge. Nevertheless, a novel approach that can be used to bypass pre-existing
immunity and secure the systemic delivery of HSV-1 OVs may involve the use of carrier cells
that have tropism for tumor-bearing tissues and in addition can protect the virus from
neutralization [212].
While the clinical studies performed so far are encouraging at this point it is difficult to
relate the clinical outcomes to any of the observations of activity in the TME. While we and
others have shown evidence of the induction of anti-tumor immune responses in animal models it
remains to be tested whether similar results can be produced in human patients, and specifically
whether the lymphocyte infiltrates after oHSV OVT are anti-viral or anti-tumoral or both.
However, it is clear that oHSV OVT is capable of significant alteration of infiltrating immune
cells, as well as circulating immune cells that would be expected to exert positive anti-tumor
immune responses. Beyond the scope of this review is a number of oHSV trials that are being
carried out in combination with established cancer therapeutics and immunotherapeutics. Finally,
it will be important to identify immunological correlates of therapeutic efficacy as these will
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inform not only the rationale design of novel oHSV but both patient selection as well as selection
of combination therapy of oHSV OVT with other anti-cancer drugs.
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CHAPTER 2
NOVEL ONCOLYTIC HERPES SIMPLEX VIRUS 1 VC2 PROMOTES
LONG-LASTING, SYSTEMIC ANTI-MELANOMA TUMOR IMMUNE
RESPONSES AND INCREASED SURVIVAL IN AN
IMMUNOCOMPETENT B16F10-DERIVED MOUSE MELANOMA
MODEL
2.1. Introduction
Immunotherapy, the targeted alteration of immunological parameters to achieve a
therapeutic outcome, has revolutionized the treatment of cancer. Immunotherapeutic approaches
to the treatment of cancer include vaccination, oncolytic virotherapy (OVT), chimeric antigen
receptor T-cells (CAR-T), and checkpoint inhibitors. While these approaches have met with
great success, there are still many drawbacks to current immunotherapeutic modalities that
include limited response rates and the serious side effects seen with CAR-T and checkpoint
inhibitors [101, 102, 213].
The first FDA approved oncolytic virus, T-Vec™, demonstrates the therapeutic potential
and safety of oncolytic virotherapy. However, thus far T-Vec™ has achieved limited response
rates [214]. More recent studies suggest that T-Vec™ monotherapy can be improved when
specific patient selection criteria are used [215]. Additionally, the ability of oncolytic viruses to
promote an infiltration of anti-tumor T-cells has been shown to improve the utility of checkpoint
inhibitors as a combination therapy [106, 209, 216]. These examples demonstrate the promise of
oncolytic virotherapy and support a need for improved oncolytic viruses that are capable of
facilitating robust and long-lasting anti-tumor immune responses.2

This chapter has been previously published as: Uche IK, Fowlkes N, Vu L, Watanabe T,
Carossino M, Nabi R, Del Piero F, Rudd JS, Kousoulas KG, Rider PJF. 2021. Novel oncolytic
herpes simplex virus 1 VC2 promotes long-lasting, systemic anti-melanoma tumor immune
responses and increased survival in an immunocompetent B16F10-derived mouse melanoma
model. J Virol 95:e01359-20. https://doi.org/10.1128/JVI.01359-20.
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Establishment or re-establishment of the cancer-immunity cycle is the basis of
immunotherapy. The cancer-immunity cycle begins with liberation of tumor-associated antigens
(TAA) via spontaneous immunogenic cell death, radiation, chemotherapy, and/or oncolytic
virotherapy among others [121]. Antigen presenting cells traffic from tumors to draining lymph
nodes to prime and activate tumor specific T-cells. Tumor specific T-cells then traffic to and
infiltrate the tumor whereby recognition of TAA on cancer cells can lead to eradication of
tumors. It is widely held that the development of tumor infiltrating lymphocytes (TIL), primarily
CD8+ T-cells, is critical for immune control of tumors [217-219].
Historically OVT was proposed largely to shrink tumors via replication and spread
through transformed cells. OVT is now, however, understood to be a bona fide immunotherapy
whereby lysis of tumor cells liberates TAAs in the context of immunogenic viral infection
leading to the development of anti-tumor immunity [122]. In support of this idea recent
immunogenetic analyses of greater than 10,000 tumors defining tumor-extrinsic signatures
capable of predicting outcomes found that gene signatures associated with host anti-viral
responses were correlated with increased survival [220]. The tumor microenvironment (TME) is
made up of a number of cellular and subcellular constituents and is now understood to be largely
responsible for mediating the immunosuppression that allows tumors to grow and in the case of
cancer, to spread [221]. Mechanistically, it is increasingly understood that the context of viral
infection can disrupt immunosuppression in the TME [103, 104, 222]. This reversal of
immunosuppression in the TME can result in the infiltration and proliferation of CD8+ T-cells
that suppress tumor growth [223, 224].
A number of virus species are being developed as oncolytic virotherapies including
NDV, measles, and adenovirus among others [225, 226]. The only FDA approved oncolytic
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virotherapy T-Vec™, is a Type 1 Herpes Simplex Virus (HSV-1) [227]. Herpes simplex viruses
possess many qualities that inform their usage as an OVT including their relative safety, large
coding capacity, highly tractable genetics system, wealth of molecular virology data, and the
ability to re-infect hosts multiple times [48, 228-230]. The natural history of HSV-1 is
characterized by the establishment of a primary infection in the epithelium with subsequent
infection of innervating axonal termini [231]. The virus then travels to the nucleus of neurons
where it will establish and maintain latent infection for the life of the host. Periodically, the
virus will reactivate from latency and cause clinical symptoms most often seen as lesions in and
around the mouth. Additionally, in a minority of cases, reactivation can cause significant
morbidity and even mortality as seen with herpes encephalitis or keratitis [232, 233].
Our laboratory has generated an HSV-1 mutant unable to enter axons via axonal termini
[32, 33, 234]. The inability to enter neurons abolishes the establishment and maintenance of a
latent infection and thus greatly improves its safety profile. This virus, VC2, possesses a
deletion of 38 amino acids in the N-terminus of the viral envelope glycoprotein K (gK), which is
highly conserved among all alphaherpesviruses [235]. We have shown that this mutation in the
N-terminus of gK precludes entry by fusion and forces the virus to enter cells via endocytosis
[36]. Additionally, VC2 possesses a deletion of amino acids 4-22 of a second envelope protein,
UL20. VC2 is currently being developed as a vaccine against both HSV-1 and HSV-2 and we
have shown that this virus is safe and protective in mouse, guinea pig, and macaque models [4044, 236].
In this manuscript we show that treatment of melanoma tumors in a modified B16F10
mouse melanoma model reduced tumor size and increased survival over control treatment.
Importantly, VC2 oncolytic virotherapy promotes a long lasting systemic anti-tumor immunity
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that is dependent on the development of an anti-tumor CD8+ T-cell response. These data support
the continued development of VC2 as a safe, effective OVT.
2.2. Materials and methods
2.2.1. Animals
Female C57BL/6J mice were purchased at ages 4 to 5 weeks from the Jackson
Laboratory (Bar Harbor, ME). All animals were fed with a regular rodent diet and housed under
standard conditions, with no more than 5 per cage under a specific pathogen-free conditions, in a
temperature-controlled room with a 12 h light and 12 h dark circle. All procedures involving
animals and their handling were conducted in accordance with the National Institutes of Health
guidelines and were approved by the Louisiana State University Institutional Animal Care and
Use Committee (IACUC reference number: 20-002).

2.2.2. Construction of the VC2 virus
The VC2 virus was constructed using the two-step double-Red recombination method
implemented on the HSV-1(F) genome cloned into a bacterial artificial chromosome (BAC), as
previously described [21]. The VC2 virus harbors mutations in two of its viral envelope proteins:
glycoprotein K (gK) and UL20 [44]. VC2 virus was grown and titrated in Vero cells (ATCC), as
described previously [39].
2.2.3. Cell culture
B16F10 murine melanoma cells were obtained from American Type Culture Collection
(Manassas, VA). B16F10 cells were grown in Dulbecco's modified Eagle's medium
supplemented with 10% filtered, heat inactivated fetal bovine serum (Gibco-BRL, Grand Island,
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NY) and 100 µg/mL Primocin (Invivogen, San Diego, CA). African green monkey kidney
(Vero) cells were cultured in DMEM containing 10% FBS and 100 µg/mL Primocin.
2.2.4. Human nectin-1 stable transduction
B16F10 cell line was transduced with a third-generation lentiviral particle packaged
vector produced by Vector Builder (Cyagen) to stably express human nectin-1. Nectin-1 was
tagged with red fluorescent protein, mCherry, and was expressed under the control of CMV
promoter. Hygromycin selection was used to enrich stable B16F10 cells expressing nectin-1.

2.2.5. Tumor engraftment and treatment regimens
Mice were anesthetized with 2% to 3% isoflurane, and B16F10n-1 cells were engrafted
orthotopically in the dermis of the dorsal left dorsal pinna, as previously reported [237]. Mice
were engrafted with 5×105 B16F10n-1 cells in 100 μL PBS. When tumors reached 50 mm3 to
100mm3, mice were intratumorally injected with either PBS or 1x106 pfu of VC2 in volumes of
100 μl every 3 days, unless otherwise indicated. Tumors were measured approximately every 2
to 3 d by using digital caliper, and tumor volumes were calculated by using the formula 1/2
(Length × Width2). Tumor bearing mice were euthanized when tumors reached greater than
1000mm3 or when mice were excessively moribund. For the abscopal experiments, 5×105
B16F10n-1 cells were engrafted in the dermis, caudal to both the left and right dorsal pinnas of
each mouse. Approximately 8 days post engraftment, when tumors reached approximately 50
mm3 to 100mm3, tumor on the left dorsal pinna was directly injected with 1x106 pfu of VC2 or
PBS. Tumor volume was monitored every 2 days and animals were euthanized when tumors
reached greater than 1000mm3 or when mice were excessively moribund.
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2.2.6. ELISPOT assay.
One day after 3rd treatment mice were sacrificed and spleens were removed. Splenocytes
(2X106) were isolated and cultured overnight with mitomycin C-treated B16F10n-1 cells (ratio
20:1). IFN-g producing splenocytes were quantified according to manufacturer instructions
using Immunospot (Shaker Heights, Ohio) Murine IFN-

Single Color ELISPOT Assay.

2.2.7. Viral titration assay
B16F10n-1 tumor bearing mice were injected intratumorally with a single dose of 1x106
PFU VC2. B16F10n-1 tumors were harvested at 0, 24, 36, 48, 60 and 72 hr post-treatment.
Tumors were weighed, and DMEM was added according to tumor weight (1mL of DMEM per
0.1g tumor) and store at -80°C until further use. Each tumor sample was subjected to sonication
using a Branson 250 Sonifier (equipped with a microtip), set at an output control of ~ 3.5 and a
duty cycle of 45, with an intermittent 10 seconds cooling on ice. Supernatants from each tumor
sample were subjected to 1:10 serial dilutions which was inoculated on a 95% confluent 12-well
plate of Vero cells and rocked for 1hr. Following rocking, infection medium was removed and
replaced with methylcellulose overlay medium (DMEM containing 0.5% methylcellulose and
5% FBS). Each plate was incubated at 37°C in an atmosphere of 5% CO2 for 3-4 days and fixed
with 3.5% formalin overnight at room temperature. Cells were washed, and then incubated with
anti-HSV-1 antibody (Agilent, Santa Clara, CA) for 1 hr, followed by the addition of polyclonal
goat anti-rabbit immunoglobulins conjugated to horseradish peroxidase (HRP) (Agilent, Santa
Clara, CA) for 30 minutes at room temperature. Viral plaques were visualized by application of a
NovaRED peroxidase (HRP) substrate (Vector, Burlingame, CA) and counted under a
microscope.
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2.2.8. Lung colonization assay
LTR or naïve mice were injected intravenously with 5x105 B16F10n-1 cells in 100 μl
PBS. After 3 weeks, mice were sacrificed, lungs were removed and the tumor colonies on the
lung surface were counted.

2.2.9. Dual immunohistochemistry (IHC)
For dual IHC, sections of FFPE tissues (4 μm) were mounted on positively charged
Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA) and processed using the automated
BOND-MAX system (Leica Biosystems, Buffalo Grove, IL) as previously described [238, 239].
Dual immunostaining for CD4 and CD8 was performed sequentially using the Bond™ Polymer
Refine Detection and Bond™ Polymer Refine Red Detection kits, respectively. Following
automated deparaffinization, tissue sections were subjected to automated heat-induced epitope
retrieval (HIER) using a ready-to-use EDTA-based solution (pH 9.0, Leica Biosystems) for 20
min at 100 C. Subsequently, endogenous peroxidase was quenched by incubating with 3%
hydrogen peroxide (5 min), followed by incubation with a recombinant rabbit anti-mouse CD4
monoclonal antibody (clone EPR19514, Abcam, Cambridge, U. K.) diluted at 1:4,000 in a readyto-use antibody diluent (Dako, Agilent Technologies, Carpinteria, CA) for 30 min at room
temperature. This was followed by incubation with a polymer-labeled goat anti-rabbit IgG
conjugated to HRP (8 min). 3,3'-diaminobenzidine tetrahydrochloride (DAB) was used as the
substrate and the slides were incubated for 10 min. Tissue sections were subsequently incubated
with a rat anti-mouse CD8a monoclonal antibody (clone 4SM15, eBioscience, ThermoFisher
Scientific, Waltham, MA) diluted at 1:1,600 in a ready-to-use antibody diluent (Dako, Agilent
Technologies) for 30 min at room temperature. Tissue sections were subsequently incubated with
a rabbit anti-rat IgG (Vector Labs, Burlingame, CA) diluted 1:1,000 for 30 min at room
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temperature followed by a polymer-labeled goat anti-rabbit IgG coupled with alkaline
phosphatase (30 minutes). Fast Red was used as the chromogen (15 minutes), and
counterstaining was performed with hematoxylin. Slides were mounted with a permanent
mounting medium (Micromount®, Leica Biosystems). Mouse spleen sections were used as
positive controls and tissue sections not incubated with primary antibodies were used as negative
controls in addition to tissue sections were the second primary antibody (anti-CD8) was omitted.
Immunostaining was semi-quantitatively scored based on the cumulative number of positive
cells in five high magnification (40X) microscopic fields.

2.2.10. In vivo T cell depletion
CD4+, and CD8+ T cells were depleted in mice by treatment with mouse anti-CD4
(Clone GK1.5), and anti-CD8a (Clone 2.43) monoclonal antibodies respectively. Rat IgG2b
isotype control (Clone LTF-2) was administered to the control group. All antibodies were all
purchased from BioXCell, West Lebanon, NH, USA. Mice were injected with 500µg of the
appropriate mAb intraperitoneally 1 day before and 2 days after B16F10n-1 tumor engraftment
and continued with maintenance intraperitoneal injections of 250µg of the appropriate mAbs
every 5 days throughout the remainder of the experiment. All immune cell depletion was
confirmed by flow cytometry.

2.2.11. Flow cytometry analysis
B16F10n-1 tumors were harvested at various time points and dissociated in gentleMACS
C-tubes (Miltenyi Biotec, San Diego, CA) containing HBSS buffer (ThermoFisher, Waltham,
MA) using a gentleMACS Octo Dissociator (Miltenyi Biotec, San Diego, CA). For enzymatic
digestion, type I collagenase from Clostridium histolyticum (0.1g/mL; ThermoFisher, Waltham,
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MA) and DNAse I from bovine pancreas (10mg/mL; Sigma-Aldrich, St. Louis, MO) was added
to each C-tube and incubated at 37oC for 30 minutes with constant shaking. The resulting
dissociated cells were then filtered through a 70-µm filter and subsequently washed with flow
cytometry staining buffer (PBS with 0.5% fetal bovine serum) to get a single cell suspension. To
reduce non-specific binding, cells were incubated with anti-mouse CD16/32 block (Tonbo
Biosciences, Clone 2.4G2) in the presence of Ghost Dye Red 780 (Tonbo Biosciences) at 4oC for
30 minutes. Subsequently, the blocked cells were washed and incubated for 30 minutes at 4°C
with the following specific antibodies: fluorescein isothiocyanate (FITC) anti-mouse CD3e
(Clone 145-2C11, BioLegend), PE-Cyanine7 anti-mouse CD4 (Clone RM4-5, Tonbo
Biosciences), allophycocyanin (APC) anti-mouse CD8a (Clone 53-6.7, Tonbo Biosciences),
BV711 anti-mouse CD25 (Clone PC61, BioLegend) and Alexa Fluor 700 anti-mouse CD45
(Clone 13/2.3, Tonbo Biosciences). Following surface staining, cells were fixed and
permeabilized using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience, San
Diego, California). After a 4°C overnight incubation in Foxp3 fixation/permeabilization buffer
(eBioscience, San Diego, California), cells were washed and re-suspended in 1X
permeabilization buffer (eBioscience, San Diego, California) containing PE anti-mouse Foxp3
monoclonal antibody (FJK-16s, eBioscience) and incubated for 2 hours at 4oC. Following
staining, cells were washed prior to flow cytometric analysis using BD LSRFortessa X-20 cell
analyzer (BD Biosciences, San Jose, CA) and FlowJo software (TreeStar, Ashland, OR). Gating
for various populations of cells was established based on fluorescence minus one (FMO)
controls.
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2.2.12. Statistical analysis
Data were analyzed using GraphPad Prism 8 Software (GraphPad Software, Inc., San
Diego, CA). Statistical analyses were performed by using the Student’s t-test and one-way
ANOVA. Animal survival is presented using Kaplan–Meier survival curves and were analyzed
using Log-rank (Mantel Cox) test. Data are expressed as means ± standard error. P values ≤ 0.05
were considered statistically significant. P-values: (*) < .05 ; (**) < .005 ; (***) < .0005 ; (****)
< .00005.

2.3. Results
2.3.1. VC2 oncolytic virotherapy reduces tumor growth and enhances survival in an
immunocompetent murine melanoma model
To study the efficacy of VC2 in a B16F10 syngeneic mouse model of melanoma we
developed a modified B16F10 melanoma model. B16F10 cells lack Nectin-1, the receptor for
HSV-1, and are thus refractory to infection by HSV [240]. To overcome this limitation B16F10
cells were transduced with lentivirus to express Nectin-1. Transduced cells (B16F10n-1) were
selected for resistance to hygromycin B and for their ability to support HSV-1 replication. In
vitro growth analysis of VC2 in B16F10 cells revealed no growth while VC2 grew to titers of
106 pfu in B16F10n-1 cells (Figure 2.1A). To determine the ability of VC2 to replicate in
engrafted tumors B16F10n-1 cells were engrafted intradermally (caudal to the ear pinna) and at
approximately 8 days post-engraftment, when tumors reached a volume of 50mm3-100mm3,
either PBS or 1x106 pfu VC2 was introduced intratumorally in a volume of 100ul. Three days
post treatment, tumors were removed, and immunohistochemistry was performed to detect the
presence of virus. Virus was readily detected in tumors treated with VC2 compared to tumors
treated with PBS (Figure 2.1B). To develop a protocol for treatment of engrafted tumors we
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determined the ability of engrafted tumors to support replication by HSV-1. To determine the
replication status of VC2 in tumors after treatment we quantified virus in once-treated tumors
that were removed at differing times post treatment (Figure 2.1C). We were able to detect input
virus at day 0 and we noted a 3-log drop in virus titer 1 day after treatment. Day 2 post
treatment, titers reached 106 plaque forming units (pfu) and after day two there was a steady
decrease in viral titers out to day 5 post-treatment (Figure 2.1C). Using this data to inform the
treatment protocol, we decided to administer VC2 intratumorally every third day (three total
treatments) to keep virus titers as high as possible (Figure 2.2A). Importantly, using this
treatment protocol we were unable to detect any virus in lung, spleen, liver, or nervous system of
treated mice after treatment 3 (Figure 2.2E).
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Figure 2.1. VC2 replicates in B16F10 tumors expressing Nectin-1. A) In vitro VC2 infection
(M.O.I. .01) of either B16F10 cells or B16F10n-1 (cells transduced with nectin-1). Supernatants
and cell pellets, were harvested at indicated times postinfection, and plaque assays were
performed to determine viral titers. B) 72 hours after treatment of engrafted tumors with either
PBS or VC2, mice were sacrificed, B16F10 tumors or B16F10n-1 tumors were excised, and
processed for immunohistochemistry and stained with anti-HSV antibody. Representative images
from three mice per group. C) At indicated days post treatment with VC2, mice were sacrificed,
B16F10n-1 tumors were removed and sonicated. Virus was quantified by plaque assay. N = 5
mice per group.
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To determine the efficacy of VC2 as an oncolytic virotherapy we performed a survival
analysis. B16F10n-1 cells were engrafted intradermally, caudal to the ear pinna, and treated
every third day for three total treatments (Figure 2.2A). When tumors reached greater than
1000mm3 or mice were excessively moribund they were sacrificed. Mice for which tumors were
treated with PBS all required sacrifice before 20 days post treatment (Figure 2.2B). In contrast,
50% of mice for which tumors were treated with VC2 survived (Figure 2.2B). Overall tumors
treated with PBS exhibited a high rate of growth prior to sacrifice (Figure 2.2C, D). Some VC2treated tumors shrank rapidly before becoming undetectable, whereas others grew steadily, albeit
much more slowly than those that were PBS-treated (Figure 2.2C, D). Due to the significant
global burden of HSV-1 infection [241], it is important to examine the efficacy of HSV-1 based
OVT in seropositive animals. To determine the effect of HSV-1 seropositivity on VC2 efficacy
in our model, mice were exposed intramuscularly to parental F strain virus 30 days prior to
engraftment and subsequent treatment of tumors with VC2. We observed no significant
differences in the efficacy of VC2 OVT between naïve mice and mice that had been previously
exposed to HSV-1 (Figure 2.2B). This is consistent with a number of reports that found no
differences in efficacy of HSV-1-derived OVT in mice that had been pre-exposed to HSV-1
[114, 242].
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Figure 2.2. VC2 reduces tumor growth rates and enhances survival in an immunocompetent
melanoma model. A) Timeline of treatment regimen. Engrafted B16F10n-1 tumors were treated,
beginning when tumors reached 50mm3-100mm3, every three days for a total of three treatments.
Mice were sacrificed when tumors reached greater than 1000mm3 or became excessively
moribund. B) Kaplan-Meier survival curves. C) Over the course of treatment with either VC2 or
PBS, tumor volumes were measured and growth rates determined until the first death. D) Image
of PBS or VC2 treated tumors removed after the third day of treatment and quantification of
tumor mass. N = 8-10 mice per group. E) Twenty-four hours after final treatment of engrafted
tumors with VC2, mice were sacrificed, B16F10n-1 tumors, nervous system, lungs, liver, were
removed and sonicated. Virus was quantified by plaque assay. N = 3 mice per group.
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2.3.2. VC2 treatment affects intratumoral T-cell populations
To determine the effect of VC2 OVT on T-cell populations in B16F10n-1 tumors, flow
cytometry experiments were performed on tumors removed one day after the third treatment with
either PBS control or VC2. Tumors were removed and single cell suspensions were stained with
antibodies against CD45, CD3, CD4, CD8 and FoxP3. As a percentage of CD45+ cells, CD8+ Tcells were found to significantly increase in tumors treated with VC2 compared to tumors treated
with PBS (Figure 2.3A). We did not detect any differences in the CD4+ populations in tumors
after treatment with VC2 as compared to treatment with PBS (Figure 2.3B).
To determine whether VC2 treatment of tumors was generating specific anti-tumor T-cell
responses. We performed an IFN-g ELISPOT assay using splenocytes extracted from mice one
day after the third treatment with PBS or VC2. Splenocytes were mixed with mitomycin C
treated B16F10n-1 cells. With splenocytes extracted from mice which had tumors treated with
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PBS we detected few spot forming colonies (Figure 2.3C). In contrast, we detected greater than
100 spot forming colonies per 2x106 splenocytes from many of the mice which had tumors
treated with VC2 (Figure 2.3C).
Regulatory T-cells (T-Reg) suppress anti-tumor responses and an abundance of these
cells is associated with a poor outcome for cancer patients [243]. These cells make a significant
contribution to immunosuppression in the TME and are a target for developing
immunotherapeutics [244]. We used flow cytometry to ask whether VC2 treatment affected Treg numbers in B16F10n-1 tumors. We found that after treatment of tumors with VC2 there was
a profound loss of T-regs as compared to tumors treated with PBS (Figure 2.3D).

A

B

C

Figure 2.3. VC2 treatment promotes B16F10n-1 specific T cells and reduces T regulatory
(Tregs) cells in the tumor. A & B) Flow cytometry quantification of intratumoral CD8+ and
CD4+ T cells one day after third treatment. C) Mixed lymphocyte assay. Mice were engrafted
with B16F10n-1 cells and treated with either VC2 or PBS as in Figure 2. One day after 3rd
treatment, spleens were removed from mice. Splenocytes (2x106) were isolated and cultured in a
20:1 ratio with mitomycin C treated B16F10n-1 cells and IFN-g producing cells were quantified
by ELISPOT assay. D) Flow cytometry quantification of intratumoral Tregs one day after the
third treatment. Relative percentages of Tregs in the tumor as a percent of CD4+ cells. N=5 mice
per group.
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We wished to determine whether T-cells in tumors after treatment with either PBS or
VC2 were infiltrating tumors or remaining in the periphery. To achieve this we performed
immunohistochemistry experiments. One day after the 3rd treatment mice were sacrificed,
tumors were excised and processed for immunohistochemistry. Tissue sections were stained
with anti-CD3 antibody to identify T-cells in tumors after treatment with either VC2 or PBS
control. It was readily apparent that VC2 treatment of tumors resulted in a greater number of
tumor-infiltrating T-cells compared to PBS-treated tumors (Figure 2.4A).
To determine whether the CD3+ cells were CD4+ or CD8+ we performed double staining
on sections from the tumors we had used for CD3 staining above. Staining of tissue revealed an
increase in cummulative numbers of both CD4+ and CD8+ T-cells in tumors treated with VC2
(Figure 2.4B). Further there appeared to be approximately twice as many CD8+ T-cells in
tumors treated with VC2.
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Figure 2.4. VC2 treatment promotes infiltration of T-cells into tumors. A) PBS or VC2-treated
B16F10n-1 tumors were removed from mice one day after the 3rd treatment and processed for
immunohistochemistry. Tissues were stained with anti-mouse CD3 (brown) antibody and a
counter stain. B) CD4+ (brown) and CD8+ (red) double staining of same tumors. Scale bar,
50μm. Immunostaining was scored based on the cumulative number of positive cells in five high
magnification (40X) microscopic fields. Representative images from 5 mice per group.
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2.3.3. T cells are essential for VC2 efficacy
T-cell responses have been shown to be critical effectors of oncolytic virotherapy
efficacy. Our flow cytometry profiling of T-cell populations over the course of oncolytic
virotherapy with VC2 suggests a possible role for T-cells in VC2 efficacy. To test the
contribution of T-cells to VC2 efficacy we performed antibody depletion assays. Mice were
depleted of either CD4+ T-cells, CD8+ T-cells or treated with isotype antibody one day prior to
engraftment, at two days post engraftment and every 5 days afterwards (Figure 2.5A). One
hundred percent of mice depleted of CD8+ T-cells and treated with VC2 required sacrifice
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within 25 days (Figure 2.5B). CD4+ T-cell depletion appeared to also be important for VC2
efficacy as 80% of mice depleted for CD4+ T-cells and treated with VC2 required sacrifice albeit
at much later time points than mice depleted of CD8+ T-cells (Figure 2.5B). Differences in
tumor growth rates were consistent with survival data (Figure 2.5C).

A

B

Figure 2.5. CD8+ T-cells are required for VC2 efficacy. A) Treatment and depletion regimen.
Mice were intraperitoneally administered 500µg of either isotype control, CD4 or CD8-depleting
antibodies 1 day before and 2 days after B16F10n-1 tumor engraftment and continued
intraperitoneal treatments of 250µg of the appropriate mAbs every 5 days. B16F10n-1 tumor
bearing depleted and control mice were treated with either VC2 or PBS as in Figure 2. B)
Kaplan-Meier survival curve and C) tumor growth rates of mice from survival study. N = 5 mice
per group.
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2.3.4. VC2 induces long-lasting, systemic anti-tumor immunity
VC2 treated mice that survived the initial engraftment were called long term responders
(LTR). We noted that LTR mice possessed a black spot where the tumor had been engrafted.
There was no palpable tumor present. To more closely examine the nature of the black spots we
performed a biopsy and H and E staining (Figure 2.6A). Pathologist examination of slides
generated from biopsied tissue revealed no tumor cells but rather a large number of macrophages
that were filled with melanin, likely the remains of the engrafted tumor.
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To determine whether treatment with VC2 endowed mice with long term immunity to the
engraftment of B16F10n-1 cells, these cells were re-engrafted intradermally contralateral to the
initial engraftment in LTR mice or naïve mice. We successfully engrafted all of the naïve mice
whereas 0/10 engraftments produced tumors in LTR mice (Figure 2.6B).
Intradermal engraftment of B16F10 cells does not readily lead to metastasis in this mouse
model. However, it is possible to introduce these cells intravenously after which B16F10 cells
are known to colonize mouse lungs [245]. To further examine the extent of anti-tumor immunity
of LTR mice we intravenously introduced B16F10n-1 cells into either naïve mice or LTR mice.
After three weeks tumors were readily detected in the lungs of naïve mice whereas only one
tumor was detected in any of the successfully treated mice (Figure 2.6C).

A

B

Figure 2.6. VC2 treatment promotes durable, systemic anti-tumor responses. A) H and E
staining of tissue removed from mice that survived initial engraftment after treatment with VC2
(LTR). B) Number of B16F10n-1 tumor bearing mice after re-engraftment. N = 5 (naïve), and 10
(LTR). C) B16F10n-1 cells were introduced intravenously into LTR (N = 13) or naïve (N = 10)
mice. Representative images of lungs from naïve and LTR mice 3-weeks post inoculation, and
quantification of colonization. LTR = long term responder.
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2.3.5. VC2 OVT decreases growth rates of distant, untreated tumors
The ability to induce anti-tumor immunity in untreated tumors that are distant from
treated tumors is referred to as “abscopal” effect [246]. To address the ability of VC2 treatment
to induce anti-tumor immunity in untreated tumors we engrafted two tumors intradermally,
caudal to each ear, of each mouse. Treatment with either PBS or VC2 was initiated on the left
tumor when these tumors reached approximately 50mm3-100mm3. Tumors treated with PBS
exhibited similar growth rates to contralateral, untreated tumors. In these mice, both tumors
continued to grow requiring sacrifice of mice within 20 days of initiation of treatment (Figure
2.7A). This was in contrast to mice in which the left tumor was treated with VC2. In these mice,
treated tumor growth rates were similar to previous experiments where only one tumor was
engrafted while the untreated tumors in these mice exhibited decreased growth rates (Figure
2.7A). While mice that had tumors treated with VC2 all eventually required sacrifice due to the
growth of untreated tumors, these mice exhibited a significant increase of 10 days in median
survival time compared to mice that had tumors treated with PBS (Figure 2.7B).
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Figure 2.7. VC2 treatment delays growth rate of untreated distal tumor and prolongs survival.
Both the left and right sides (caudal to the ear pinnae) of mice were engrafted intradermally with
5x105 B16F10n-1 cells. Tumors on the left were treated with VC2 every three days for a total of
three treatments. Mice were sacrificed when either tumor reached greater than 1000mm3 or mice
became excessively moribund. A) Individual tumor growth rates and B) Kaplan-Meier survival
curve. Median survival time PBS (13) and VC2 (23). N = 10 mice per group.
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2.4. Discussion
Beyond safety, an important characteristic of an effective oncolytic virus is the ability to
induce strong, durable and systemic anti-tumor cell-mediated immune responses. Our principal
findings are that in an aggressive B16F10-derived melanoma model, VC2 OVT slows tumor
growth rates, facilitates greater than 50% survival, and promotes long-term, systemic anti-tumor
immunity. Furthermore, our depletion and functional studies strongly suggest that the efficacy
of VC2 OVT is due to its ability to induce anti-tumor CD8+ T-cells.
The induction of anti-tumor CD8+ T-cells is a primary goal of immunotherapies
including OVT. Many herpesvirus-derived OVT have demonstrated significant anti-tumor
CD8+ T-cell responses as a mechanism of their efficacy [48, 132, 242, 247]. A recent study of
the efficacy of T-Vec™ in combination with checkpoint inhibitors found that the infiltration of
CD8+ T-cells into tumors was highly correlated with individuals who responded to combination
therapy [248]. While not explicitly tested in our experiments the immunity to intravenous
B16F10 challenge of LTR mice suggests the development of significant CD8+ T-cell memory
responses.
Evidence of the importance of CD4+ T-cells in our model is suggested by our depletion
studies in which depletion of CD4+ T-cells resulted in decreased efficacy of VC2 OVT. We were
able to detect statistically significant increases in intratumoral CD4+ T-cells via IHC. However,
we were unable to support this via flow cytometry. We suggest that IHC examination is better
suited to discriminate intratumoral CD4+ T-cells from CD4+ T-cells that are restricted to the
tumor periphery. It is also important to note that CD4+ T-cells have been demonstrated to
facilitate optimal anti-tumor CD8+ T-cell responses and that this role for CD4+ T-cells is not
necessarily restricted to intratumoral CD4+ T-cells [249, 250]. As such, our data is consistent
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with a role for CD4+ T-cells in optimization of an anti-tumor immune response during VC2
OVT in our model.
What distinguishes VC2 from other herpesvirus-derived OVT, beyond its
efficaciousness, is that it does not express transgenes such as IL-12 or GM-CSF. These
transgenes were initially proposed to promote the infiltration of immunogenic cells, such as
dendritic cells, that may promote development of anti-tumor immunity. This is a significant
difference between VC2 and other herpesvirus-derived OVT, including T-Vec™. Early
approaches to the generation of safe herpesvirus-derived OVT included deletion or mutation of
genes that were found to attenuate virus replication in normal tissues but did not affect virus
replication and spread through transformed cells [111, 114]. More recent approaches to
restriction of OVT to transformed cells include the insertion of miRNA target sites in critical
HSV genes, use of specific promoter to express critical HSV genes and receptor retargeting [46,
48, 208, 251]. However, all of these approaches possess limitations including the possibility of
reversion of attenuation in addition to compromised replicative potential and thus efficacy. VC2
replicates to similar viral titers with its parental virus HSV-1(F) with the exception that it cannot
enter into neuronal axons and establish latency in ganglionic neurons. More recently it has been
proposed that more fully replication competent oncolytic herpesviruses, such as VC2, may
exhibit greater efficacy as OVT [48, 242, 252]. Our results are in agreement with this idea and
we speculate that the ability of VC2 to replicate well in non-neuronal cells contributes to its
efficacy and what may be its enhanced immunogenicity in comparison to other herpesvirusderived OVT.
For viral based therapies such as OVT, pre-existing immunity is a concern as pre-existing
immunity may result in a decrease in efficacy. This is due to the effect anti-viral immunity has
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on the ability of OVT to induce an anti-tumor immune response prior to being eliminated by an
adaptive immune response. This is of particular concern with HSV-1 based therapeutic and
prevention strategies due to the high prevalence of HSV-1 exposure in the human population
[241]. We demonstrate here that pre-exposure of mice to HSV-1 prior to engraftment and
subsequent treatment has no effect on VC2 OVT in our model. This is consistent with a number
of groups reporting similar results [114, 242]. It is worth noting that other groups have
successfully leveraged pre-existing anti-viral immunity to enhance therapeutic outcome [211,
253, 254]. It has been suggested that this may be particularly true for herpesviruses which as
part of their replicative strategy periodically reactivate and spread in the presence of significant
adaptive immune responses [211]. As such, rather than being a hindrance to herpesvirus-based
OVT, pre-existing immunity may enhance the efficacy of such therapies.
In addition to the ability of VC2 to replicate well in non-neuronal cells it may be that the
alteration of initial host-pathogen interactions due to the mutations in HSV-1 envelope proteins
gK and UL20 in VC2 lead to differential host responses that are more immunogenic than during
wild type virus infection. VC2 enters into epithelial and other cell types exclusively via
endocytosis that may enhance innate immune responses leading to enhanced cellular responses.
This is supported by our finding that intramuscular immunization with VC2 fully protected
against ocular challenge of mice with the human clinical strain HSV-1(McKrae), while
immunization with its parental virus HSV-1 (F) conferred only partial protection [41]. The
development of vectors for the induction of strong T-cell mediated immune responses are needed
for use in vaccination against infectious disease and cancer [255]. The potential increase in
immunogenicity may facilitate the translational potential of VC2 to serve as a vaccine vector and
OVT.
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We show here that VC2 treatment significantly reduced the number of T-Regs in tumors.
This strongly suggests that VC2 treatment reverses the immunosuppression in the TME as a
mechanism of its efficacy. VC2-treated mice which survived the intradermal engraftment
responded very quickly (within days) to treatment. This also suggests that rather than the
development of a de novo antitumor T-cell response the efficacy of VC2 treatment in our model
is due to a reversal of immunosuppression leading to rapid expansion of anti-tumor T-cells in
VC2-treated tumors. In this respect it is important to note that our model can be used to study the
cellular, molecular and immunological mechanisms of oncolytic virus efficacy. Specifically, it
will be important to determine how VC2 affects the TME as a component of efficacy. A major
focus of our work moving forward will be to examine the cellular and subcellular constituents of
the TME during VC2 OVT. These studies will inform the rational design of improved oncolytic
viruses for the treatment of human cancers.
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CHAPTER 3
UTILITY OF A RECOMBINANT HSV-1 VACCINE VECTOR FOR
PERSONALIZED CANCER VACCINES
3.1. Introduction
It is currently understood that cancers result from individual cellular transformation
events resulting in genetically and phenotypically unique tumors even within the same tissue
environment [256]. This is problematic for the development of therapeutic or prevention
strategies that seek to treat patient populations based on common features of tumors such as their
tissue of origin. It is not surprising therefore, that current drugs for treating cancer only work for
a small number of patients with a given cancer type [257]. Thus, a personalized medicine
approach is needed to tailor immunotherapies that are based on identifiable characteristics of
patient-specific tumors.3
Current molecular diagnostics, including genomic and proteomic tools, allow us to
employ greater precision in the design and delivery of anti-cancer treatments and therapies [258260]. These tools avail physicians and scientists with incredible amounts of information
regarding mutations that are unique to a particular patient. Examples include the identification
of druggable pathways that result from such mutations, or the targeting novel kinase fusions in
various cancer types [258, 261]. Additionally, these tools can be used to identify so-called tumor
associated antigens (TAAs) [262]. TAAs are the protein products of mutated genes that are not
found in the proteome of healthy, non-transformed cells. TAAs result from genetic mutations
and are unique to specific patients. As the immune system has evolved to discriminate self from
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and Rider PJ (2022) Utility of a Recombinant HSV-1 Vaccine Vector for Personalized. Cancer
Vaccines. Front. Mol. Biosci. 9:832393. https://doi.org/10.3389/fmolb.2022.832393
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non-self and eliminate non-self, TAAs can be used to target host immune responses to cells that
bear these TAAs [262]. This approach results in a “personalized” therapy.
Personalized therapies include CAR-T-cells, bispecific antibodies, and several
approaches to induce de novo TAA specific immune responses via mRNA and vaccines, peptide
vaccines and viral vectored TAAs [258, 262-265]. While there are currently no FDA-approved
TAA vaccines, many groups have reported successes in clinical and pre-clinical work, and there
is a great deal of interest and activity in this area [266].
Regarding viral vectored TAA vaccines, there are several approaches currently being
pursued [267]. Viral vectors must possess both safety as well as immunogenicity. There are
several attributes of human herpesviruses that inform their use as vaccine vectors: 1) they can
infect humans in the presence of a significant anti-viral host response, 2) their relative safety, 3)
their large size allowing the insertion of multiple transgenes within their viral genomes without
compromising viral replication and infectivity, 4) the ease of genetic manipulation allowing the
rapid and efficient generation of recombinant viruses, 5) the availability of anti-herpes drugs to
control potential breakthrough infections, and 6) availability of a significant body of knowledge
regarding the molecular biology of human herpesviruses which allows targeted manipulation of
the viral genome to avoid downregulation of specific immune responses while augmenting others
[268].
Our laboratory has developed the HSV-1 vaccine vector strain, VC2 [44]. Specific
mutations in VC2 glycoprotein K (gK) and the UL20 membrane protein abrogate its ability to
infect neurons and establish latent infection [32]. The inability to establish latent infection and
subsequently reactivate, is a unique safety feature. We have shown in several animal trials,
including mouse, guinea pig, and non-human primate studies, that VC2 is a safe and
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immunogenic vaccine strain [41-43]. We have further shown that VC2 confers protection of
against lethal HSV genital and ocular infection [40, 41, 44].
Previously, we reported that VC2 induced potent anti-tumor immune responses when
administered intratumorally to melanoma tumors in immunocompetent mice [123]. Herein, we
evaluated the utility of VC2 as a vaccine vector for prophylactic and therapeutic anti-cancer
applications. To this end we generated the recombinant virus, VC2-OVA, expressing the
immunogenic OVA peptide fused in-frame to the amino-terminus of the VP26 viral capsid
protein. This allows maximal expression of the immunogen in infected cells, as well as its
incorporation into the virion particle. We evaluated the efficacy of VC2-OVA in a syngeneic
mouse model of melanoma. Specifically, we took advantage of widely used experimental mouse
models of melanoma that express ovalbumin: B16cOVA (melanoma). Finally, we evaluated the
differences between intradermal, subcutaneous and intramuscular routes of vaccination with
VC2-OVA. Vaccination with VC2-OVA prevented the growth of engrafted tumors in both
prophylactic and therapeutic settings. Importantly, our results show that the specific route of
vaccination had a profound impact on the success of prophylactic treatment. Taken together
these data demonstrate the potential of the VC2-vectored approach for personalized anti-cancer
therapeutics.
3.2. Materials and methods.
3.2.1. Animals
Four- to five-week-old female C57BL/6J mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). All mice were maintained in pathogen-free facilities. Protocols
involving animals were reviewed and approved by the Louisiana State University Institutional
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Animal Care and Use Committee (IACUC), and all animal experiments were performed in
accordance with the protocols.

3.2.2. Construction of the VC2-OVA virus
The bacterial artificial chromosome (BAC) plasmid VC2 was used to construct VC2OVA as previously described [44]. High-efficiency markerless DNA manipulation of VC2 was
achieved using two-step red-mediated recombination [269]. Oligonucleotides used in the
construction of the recombinant virus are presented in Table S1. Recombinant HSV-1 was
recovered after BACs were transfected into Vero cells using Lipofectamine according to the
manufacturer's protocol. DNA was extracted from viral stocks, and VP26 was sequenced to
ensure the presence of the desired mutation. Virus for experimentation was purified as follows:
Vero cells were infected and at full cytopathic effect (CPE), cells and supernatant were
harvested. The cellular portion was separated from the supernatant by centrifugation at 4,000
RPM for 10 minutes. The supernatant was removed and the cell pellet was lysed by freezing and
thawing of the pellet 3 times. The supernatant was added to the lysed cellular portion followed
by a second round of centrifugation at 4,000 RPM for 10 minutes. The supernatant was
aliquoted and titered to perform experiments.

3.2.3. Western blot analysis
Vero cells were uninfected or infected at an MOI 1 with either VC2 or VC2-OVA for 24
and 48 hours in a 6 well plate. Adherent cells were washed 3x in PBS followed by lysis in 200
μL of NP40 lysis buffer with protease/phosphatase inhibitors. Twenty microliters of whole cell
lysate were then mixed with Laemmli sample buffer (Bio-Rad) and 1 μL of β-mercaptoethanol to
a final 1x concentration. These mixtures were then boiled at 100°C for 10 minutes and cooled on
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ice before loading into a 12% Mini-PROTEAN TGX precast gel (Bio-Rad) and separated for 1
hour at 100V in 1x Tris-Glysine-SDS buffer (Bio-Rad). Separated protein was then transferred to
a nitrocellulose membrane in 1x Tris-Glysine + 20% methanol (Bio-Rad). The membrane was
then blocked for 30 minutes in 5% BSA in PBS-T. Rabbit anti-VP26 (Kind gift from Prashant
Desai, Johns Hopkins), was diluted 1:1000 in 5% BSA PBS-T and applied to the membrane and
incubated overnight at 4°C while rocking. The next day, the membrane was then washed 3x with
PBS-T and secondary goat anti-Rabbit IgG (Abcam: ab6721) diluted 1:1000 in 5% BSA PBS-T
applied to the membrane and incubated at room temperature for 1 hour. The membrane was then
washed 3x in PBS-T and visualized using ECL Western Blot Substrate (Pierce) and exposure
film.

3.2.4. Cell culture
The ovalbumin-expressing B16 melanoma cell line (B16cOVA) was a kind gift from Dr.
Timothy N.J. Bullock (University of Virginia, Charlottesville, Virginia, USA). B16cOVA cells
were grown in RRPMI 1640 medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10%
filtered, heat inactivated fetal bovine serum (Gibco-BRL, Grand Island, NY), 100 µg/mL
Primocin (Invivogen, San Diego, CA), plus 10 µg/mL Blastocydin (Invitrogen Life
Technologies, Grand Island, NY). African green monkey kidney (Vero) cells were cultured in
DMEM containing 10% FBS and 100 µg/mL Primocin.

3.2.5. Tumor engraftment and treatment regimens
For prophylactic assessment, mice were not treated; intramuscularly; intradermally; or
subcutaneously vaccinated with 1x106 pfu of VC2 or 1x106 pfu of VC2-OVA in volumes of
100ul. Fourteen days after prime immunization, booster immunizations were administered. Six

72

days post-boost, mice were engrafted with 5×105 B16cOVA cells in 100 μL PBS orthotopically
in the dermis of the dorsal left dorsal pinna. Tumors were measured approximately every 2 to 3
days by using a digital caliper when tumors reached 50 mm3 to 100mm3. Tumor volumes were
calculated by using the formula 1/2 (length × width2). Tumor bearing mice were euthanized
when tumors reached greater than 1000mm3 or when mice were excessively moribund. To assess
the therapeutic effect, mice were injected intravenously with 5x105 B16cOVA cells in 100 μl
PBS, and then intramuscularly; intradermally; or subcutaneously vaccinated the next day for two
consecutive days. Mice were sacrificed 3 weeks post engraftment, and lungs were removed and
the tumor colonies on the lung surface were counted.
3.2.6. ELISPOT assays
One day after boost vaccination, mice were sacrificed, and spleens were removed.
Splenocytes (7.5 x 105) were isolated and cultured overnight with either gB peptide (1 μg/ml) or
ovalbumin (OVA257–264 [SIINFEKL]) peptide (1 μg/ml). IFN-g-producing splenocytes were
quantified according to the manufacturer’s instructions using an Immunospot (Shaker Heights,
OH) murine IFN-g single-color ELISPOT assay.
3.2.7. Flow cytometry analysis
The following antibodies (clones) were used: Fluorescein isothiocyanate (FITC)-TCR β
(H57-597), Allophycocyanin-Cyanine7 (APC-Cy7)-CD8a (53-6.7), Alexa Fluor 700-CD45R
(RA3-6B2), Phycoerythrin-Cyanine7 (PE-Cy7)-CD62L (MEL-14), PE-CD127 (A7R34), PECy7-IFN- g (XMG1.2) were from Tonbo Biosciences (San Diego, CA); Peridinin Chlorophyll
Protein Complex-eFluor 710 (PerCP-eFluor 710)-CD4 (RM4-5) was from eBiosciences (San
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Diego, CA); APC-KLRG1 (2F1/KLRG1), Brilliant Violet (BV)421-CD44 (IM7), and BV421TNF-α (MP6-XT22) were from BioLegend (San Diego, CA).
For surface staining, cells were stained with the appropriate antibodies in phosphatebuffered saline (PBS), in the presence of Fc block (CD16/32; BioLegend) and fixable viability
dye (Ghost Violet 510; Tonbo Biosciences). For intracellular cytokine staining (ICS), cells were
stimulated as indicated, fixed and permeabilized using intracellular fixation and permeabilization
buffer (BioLegend) and stained with the appropriate antibodies as per the manufacturer’s
instructions. Flow data was acquired on a BD LSRFortessa (BD Biosciences), and data analysis
was done using FlowJo Software (Tree Star, Ashland, OR).
3.2.8. Statistical analysis
All statistical analyses were done using GraphPad Prism 9 Software (GraphPad Software,
Inc., San Diego, CA). Analysis of data between three or more groups was performed by using
one-way ANOVA. Survival data were presented using Kaplan–Meier survival curves and
differences among groups were analyzed by the log rank test. A P-value of 0.05 or less was
considered statistically significant in all analyses herein.
3.3. Results
3.3.1. Construction and characterization of ovalbumin expressing virus
We wished to fully exploit the potential of viruses to deliver antigen and promote strong,
broad, and effective anti-immunogen responses in the host. To this end, we fused the
immunogenic portion of chicken egg ovalbumin to VP26, the minor capsid protein of HSV-1
(Figure 3.1A). Ovalbumin is a common experimental immunogen with an extensive history of
use for studying immunogenicity of novel vaccine approaches [270]. VP26 is present at
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approximately 900 copies in each virion [271]. This means that in an inoculum of 106 pfu we can
deliver nearly 109 OVA-VP26 antigens. However, this extrapolation is likely an underestimation
due to a particle to pfu ratio for tissue culture-derived HSV-1 reported to be 100:1 [272]. Further,
the fusion of an antigen to the viral particle allows access to the exogenous antigen presentation
pathway to promote the development of TH2 responses in addition to traditional TH1 responses
to viral vectored antigens. Using BAC mutagenesis, a portion of ovalbumin containing the
canonic CD8+ peptide (SIINFEKL, OVA257-264) was fused to the amino terminus of VP26 to
generate VC2-OVA.
To confirm expression of the fusion protein in recovered VC2-OVA, Vero cells were
infected at a multiplicity of infection of 1. Twenty-four- and forty-eight-hours post-infection,
protein lysates were prepared, and a western blot was performed. Using an antibody to detect
VP26 we readily observed a protein of the expected size (12kDA [273]) in lysates from cells
infected with parental VC2 virus (Figure 1B). However, in lysates from cells infected with VC2OVA we observed a protein at an apparent molecular mass of approximately 25 kDa, the
expected molecular weight of the VP26-OVA fusion protein (Figure 3.1B).
To determine any effect of fusing ovalbumin to VP26 on viral replication we performed a
multi-step growth curve comparing parental VC2 virus and VC2-OVA. Vero cells were infected
at an MOI of .01 and cells were harvested at 0, 4, 12, 24 and 48 hours post infection. Standard
plaque assays were performed to quantify virus in cell lysates. We were unable to identify any
difference in viral replication between parental and VC2-OVA viruses (Figure 3.1C).
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Figure 3.1. Construction of VC2-OVA virus. (A) VC2-OVA. (B) Expression of OVA VP26
fusion protein. Vero cells were infected at a multiplicity of infection of 1. Twenty-four- and
forty-eight-hours post infection, protein lysates were prepared and analyzed by western blot. The
blot was stained with antibody to VP26. (C) Growth curve of VC2-OVA and parental VC2
viruses. Vero cells were infected at a multiplicity of infection of 0.01. Supernatants and cell
pellets were harvested at indicated times post infection, and plaque assays were performed to
determine viral titers.
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3.3.2. Immunogenicity of VC2-OVA in mice
To test the ability of VC2-OVA to induce OVA-specific immune responses we
vaccinated mice with VC2-OVA. After 14 days, mice received a second vaccination (boost) with
VC2-OVA or the parental virus. Seventy-two hours post boost vaccination, mice were sacrificed
and splenocytes were harvested (Figure 3.2A). Splenocytes were incubated with either HSV-1
glycoprotein B peptide or SIINFEKL peptide and ELISPOT analysis was performed. The gB
peptide is a dominant CD8+ T-cell epitope [274] and serves as a positive control. We observed
that vaccination with VC2 and VC2-OVA, induced high levels of gB specific immune responses
(Figure 2B). However, only in splenocytes from mice vaccinated with VC2-OVA was an OVA
specific T cell response detected (Figure 3.2B). Interestingly, there was no significant difference
in these responses induced by the different vaccination routes in those animals. Further, we
observed that intradermal and subcutaneous vaccination with VC2-OVA, significantly induced
increased CD8+ T cell with an effector/memory phenotype (CD44high CD62L-) compared to
vaccination with parent VC2 virus (Figure 3.3B).
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A

B

Figure 3.2. Vaccination with VC2-OVA induces OVA specific T cell response and increased
CD8+ effector/memory T cells. A) Timeline of treatment regimen. Mice were untreated or prime
vaccinated intramuscularly, or intradermally, or subcutaneously with 1x106 pfu of VC2-OVA or
parental VC2 virus. Fourteen days later, boost immunizations were administered. Seventy-two
hours post boost, mice were euthanized, and their spleens were harvested. B) Isolated
splenocytes (7.5 x 105) were cultured overnight with either gB peptide (1 μg/ml) or OVA257–
264 [SIINFEKL]) peptide (1 μg/ml), and IFN-g producing cells were quantified by ELISPOT
assay. C) Isolated splenocytes were surface stained and assayed by flow cytometry to quantify T
cells with naïve or effector/memory phenotype. N = 3-5 mice per group. Data were analyzed
using one-way ANOVA. **, P < 0.01, ***, P < 0.001.
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3.3.3. Efficacy of VC2-OVA in an experimental mouse model of melanoma
We have previously shown the efficacy of parental VC2 in intratumoral treatment of
mice engrafted with modified B16F10 melanoma [123]. In those previous experiments, we
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achieved between 50 and 80% cure rates. To investigate whether the expression of a tumorassociated surrogate protein can be used to augment anti-tumor immune response, we employed
B16F10 cells which express OVA in conjunction with the VC2 OVA expressing virus
administered by direct inoculation into engrafted B16cOVA tumors. There were no significant
differences between parental VC2 and VC2-OVA (data not shown). We believe that this is due
to the very high cure rate with VC2 treatment that could not be significantly augmented by the
presence of the OVA antigen. Next, we tested the efficacy of VC2-OVA in preventing tumor
growth in mice that had been vaccinated before engraftment of B16cOVA tumors. The relevance
of this approach may be seen in a case where surgical resection of a tumor is followed by
vaccination against recurrence. In these experiments we compared the efficacy of VC2-OVA
using three distinct vaccination routes: intramuscularly (IM), subcutaneously (SC), or
intradermally (ID). We chose this approach as recent data suggests that the efficacy of
vaccination can be dependent on the route of vaccination [275]. Animals were vaccinated twice,
14 days apart, before tumor engraftment 6 days after the second vaccination (Figure 3.3A). Mice
vaccinated with VC2 (regardless of route of vaccination) were sacrificed 35 days post
engraftment (Figure 3.3B). In contrast to mice vaccinated with parental VC2, all mice vaccinated
with VC2-OVA before engraftment had significantly increased median survival times.
Interestingly, mice vaccinated with VC2-OVA exhibited survival times that were dependent on
route of vaccination. Ninety percent of mice that were ID vaccinated before engraftment arrested
tumor growth and survived. Twenty percent of mice that were vaccinated IM survived while
none of the mice vaccinated SC survived. Tumor growth rates were consistent with the results of
survival with few mice vaccinated intradermally exhibiting tumor growth at all while
intramuscular vaccination resulted in slower tumor growth rates than subcutaneous vaccination
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(Figure 3.3C). For control purposes, we engrafted mice previously vaccinated with either VC2 or
VC2-OVA with B16F10 cells which do not express ovalbumin. In these experiments there were
no differences in survival times or tumor growth rates, regardless of vaccination with VC2 or
VC2-OVA (Figure 3.3D, E).

A

B

Figure 3.3. The prophylactic effect of VC2-OVA in B16cOVA tumor model. A) Timeline of
treatment regimen. Mice were untreated or prime vaccinated intramuscularly, or intradermally,
or subcutaneously with 1x106 pfu of VC2-OVA or parent VC2 virus. Fourteen days later, booster
immunizations were administered. Six days post vaccination, mice were engrafted with 5x105
B16cOVA or B16F10 tumor cells. Mice were observed for tumor growth. Mice were sacrificed
when tumors reached greater than 1,000 mm3 or when the mice became excessively moribund.
Kaplan-Meier survival curves (B, D). Tumor volume and growth rates was measured every 2 to
3 days (C, E). N = 5-10 mice per group. **, P < 0.001, ***, P < 0.001, ****, P < 0.0001.
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Next, we investigated the efficacy of VC2-OVA when used in a therapeutic context,
where engraftment preceded treatment. In these experiments, B16cOVA cells were inoculated
intravenously. The introduction of these cells intravenously leads to colonization of the lungs by
the B16F10 cells resulting in tumors that can be enumerated approximately 3 weeks post
engraftment. This approach is a commonly used approach to test intervention strategies for
metastasis and the development of systemic anti-tumor immunity. B16cOVA cells were
administered intravenously, and mice were treated with either VC2 or VC2-OVA IM, SC, or ID
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two days post tumor administration (Figure 3.4A). Twenty-one days post engraftment, mice were
sacrificed and colonies of B16cOVA cells in the lungs were enumerated (Figure 3.4B). Mice
that were left untreated or treated with VC2 had significantly more tumor colonies in their lungs
than mice treated with VC2-OVA (Figure 3.4B, C).
A

B

Figure 3.4. Therapeutic response of VC2-OVA in B16cOVA tumor model. A) Timeline of
treatment regimen. Mice were intravenously challenged with 5x105 B16cOVA tumor cells. The
next 2 days, mice were treated with either VC2-OVA or VC2 through the different vaccination
routes. Nineteen days post treatment, mice were euthanized and tumor colonies on the lung
surface were quantified. B, C) Representative images of lungs from untreated, VC2, VC2-OVA
treated mice 3 weeks postinoculation and quantification of colonization. N =10 mice per group.
Data were analyzed using one-way ANOVA. **, P < 0.01,***, P < 0.001, ****, P < 0.0001, ns
= not significant.
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3.3.5. Efficacy of VC2-OVA in an experimental mouse thymoma model
It is important to test novel therapeutics in multiple models. To this end, we chose a
thymoma model to test the efficacy of VC2 as a potential cancer vaccine. EL4 cells are mouse
malignant T cell lymphoma cells. We obtained EG.7-OVA which are EL4 cells that express
ovalbumin from ATCC. Similar to the B16cOVA model described above we vaccinated mice
twice prior to engrafting E.G7-OVA cells intradermally (Figure 3.5A). We performed a survival
analysis and found that compared to mice vaccinated with VC2 in which all groups of mice had
to be sacrificed, groups vaccinated with VC2-OVA had some percent survivors. Similar to
B16F10 OVA experiment, mice vaccinated SC with VC2-OVA had the highest number of
surviving mice at greater than 75% survival (Figure 3.5B). In contrast to our results with
B16cOVA, mice vaccinated with VC2-OVA SC had an almost 75% survival rate whereas mice
vaccinated with VC2-OVA IM had only an approximately 20% survival rate. Tumor growth
rates were consistent with our survival rates (Figure 3.5C). As a control we engrafted parental
EL4 cells in vaccinated mice. All of these mice required sacrifice regardless of whether they
were vaccinated with VC2 or VC2-OVA (Figure 3.5D, E). Additionally, tumor growth rates and
survival in these control experiments was unaffected by route of vaccination.
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Figure 3.5. The prophylactic effect of VC2-OVA in E.G7-OVA tumor model. A) Timeline of
treatment regimen. Mice were not treated or prime vaccinated intramuscularly, or intradermally,
or subcutaneously with 1x106 pfu of VC2-OVA or parent VC2 virus. Fourteen days later, booster
immunizations were administered. Six days post vaccination, mice were engrafted with 5x105
E.G7-OVA or EL4 tumor cells. Mice were observed for tumor growth. Mice were sacrificed
when tumors reached greater than 1,000 mm3 or when the mice became excessively moribund.
B, D) Kaplan-Meier survival curves. C, E) Tumor volume and growth rates were measured every
2 to 3 days. n = 4 to 5 mice per group.
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3.4. Discussion
The identification of safe, and immunogenic vaccine vectors capable of inducing potent
immune responses is critical to the development of anti-infectious disease and anti-cancer
intervention strategies [255]. Previously, we demonstrated that the novel HSV-1 (VC2) vaccine
vector, can be used to induce potent anti-tumor immune responses in a mouse model of
melanoma [123]. Herein, we extend our previous findings by demonstrating that VC2 can be
readily adapted to promote TAA-specific immune responses capable of extending mouse
survival and decreasing tumor growth rates.
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Of particular interest is our finding that the route of vaccination was a large factor in the
efficacy of treatment. Intradermal route of vaccination proved best in our B16cOVA melanoma
model in a prophylactic context. Intramuscular route of vaccination proved to be the least
effective in both extending survival and reducing tumor growth rates. It is unclear why
intradermal delivery of the virus produced a more efficient vaccination approach. It has been
documented that immune responses are affected by the route of vaccination [275, 276]. There are
differing reports on whether there is an actual difference in the magnitude or quality of adaptive
immune responses generated by differing routes of administration [277, 278]. What makes our
study particularly compelling is that we have a functional readout on the route-dependent
promotion of anti-tumor responses based on survival and tumor growth rates. Our data strongly
suggest that there are significant differences in the outcome of treatment based on the route of
administration.
It is important to point out that route of administration is not a one size fits all problem.
Likely each route of administration induces specific types of immunity that may be individually
suited to protect against different infection and tumor types. Along these lines we note that our
studies used two different engraftment sites: intradermal and intravenous. While we saw large
differences in route of administration for the intradermally engrafted tumors we didn’t find any
difference for the route of administration when tumors were engrafted intravenously. These
findings suggest that the route of administration may be an important consideration for infections
and tumor types at some sites but not others.
In these experiments we have used an experimental immunogen, OVA, to evaluate the
utility of HSV-1 in general, and VC2 specifically, as a vector to deliver tumor associated
antigens for treatment of cancer. It is important to note that the clinical utility of our approach
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will depend on the identification of similarly immunogenic tumor associated antigens in human
patients. The identification of such antigens in human tumors is an active area of investigation
with encouraging results [262, 279]. The identification of such antigens is however fruitless
without the development of technologies, such as ours, to deliver TAAs to patients. Future
experimentation should therefore focus on using highly immunogenic vectors to target tumor
specific TAAs.
In summary, we find that there is significant evidence to pursue viral vectored TAA
delivery in general and VC2-derived TAA vaccines specifically. VC2 has proven safe and
efficacious as an HSV vaccine in a variety of animal models and preparations are ongoing for a
pilot in-human trial. As we have shown that VC2 works very well as an oncolytic virotherapy
we are excited about the prospect of using VC2 as a combination OVT and personalized vaccine
for the treatment of human and animal cancers.
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CHAPTER 4
SUMMARY AND CONCLUDING REMARKS
4.1. Introduction
The poor outcomes and limited efficacy associated with standard cancer treatments and other
known immunotherapeutic approaches necessitates the need for developing better cancer
treatment strategies. Oncolytic virotherapy (OVT) has gained significant support as a treatment
platform for cancer as it can provide improved outcomes and fewer side effects. OVT involves
the use of oncolytic viruses (OVs) to kill cancer cells and in addition, stimulate the activation of
the host antitumor immune response [268]. To date, Talimogene laherparepvec (T-VEC;
Imlygic™), a genetically modified form of the herpes simplex virus-1 (HSV-1) JS-1 strain is the
only OV approved by the Food and Drug Administration (FDA) for treating melanoma [113,
114]. Although, the safety and therapeutic potential of T-VEC has been demonstrated, it
produced limited response rates. In order to develop novel and better oncolytic viral vectors that
will overcome the limitations of current OVs it is necessary to understand the cellular and
molecular mechanisms of their antitumor efficacy and how they alter the tumor
microenvironment (TME).
Our laboratory has produced the live-attenuated HSV-1(VC2) vaccine strain, engineered to
contain mutations in two viral envelope proteins: glycoprotein K (gK) and UL20 [44]. These
mutations prevent the ability of viral glycoprotein gB to mediate membrane fusion required for
virus entry and virus spread via cell-to-cell fusion (syncytia formation). Importantly, these
mutations render the virus unable to enter into neurons via their axonal termini both in vitro and
in vivo [32, 33]. VC2 retains the properties of a replication-competent vector, because it can
enter into fibroblasts, epithelial and other cells via endocytosis and produce nearly wild-type
viral titers [36] while there is practically no safety concern of establishing latent infection or
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reactivation which are associated with other currently used oncolytic herpesvirus vectors.
Importantly, published, and ongoing experiments from our laboratory have revealed that VC2
induces a stronger immunogenic response compared to the parental wild-type virus [41-45, 280].
Taken together, we believe that the good safety, efficacy, and immunogenicity profiles exhibited
by VC2 makes it a promising anti-cancer biological agent.
Presented in this dissertation are two experimental studies investigating VC2, as a novel
OVT for cancer treatment, using different mouse models. Chapter 1 provides an introduction of
the life cycle of herpes simplex virus, and tissue tropism for the virus, as well as the pathogenesis
and immune responses induced by virus. Furthermore, we described how HSV-1-derived OVTs
affect the tumor microenvironment (TME) to promote to anti-tumor immune responses
(published in the peer reviewed open access journal, Viruses). The studies presented in chapter 2,
describes how VC2 OVT promotes long-lasting anti-melanoma tumor immune responses, and
increased survival in an immunocompetent B16F10-derived mouse melanoma model (published
in the peer reviewed journal, Journal of Virology). Finally, in chapter 3, we investigated whether
VC2 could be used to deliver tumor associated antigens to promote enhanced anti-tumor directed
responses (manuscript published in the Frontiers of Molecular Sciences Journal). Below are the
summaries of the results from each experimental study demonstrating significant clinical
potential for VC2.
4.2. Summary of results
In chapter 2, we investigated the efficacy of VC2 as an OVT in a syngeneic B16F10-derived
mouse model of melanoma. First, we engineered the B16F10 tumor cells to express nectin-1, the
major receptor for HSV-1. In vitro growth analysis indicates that these modified cells (B16F10n1) were highly susceptible to infection with VC2 and supported the growth of the virus,
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compared to the B16F10 cells where no growth was observed. Additionally, our
immunohistochemistry analysis revealed that B16F10n-1 tumor cells also supported VC2 growth
in vivo. We found that intratumorally treatment with VC2 slowed engrafted B16F10n-1 tumor
growth rates and significantly enhanced survival times over control mice treated with phosphatebuffered saline (PBS). VC2-treated mice that survived initial tumor engraftment were able to
reject a second tumor challenge. These long-term responders were also resistant to lung
colonization (experimental metastasis) of tumor cells, when intravenously challenged via tail
vein. Furthermore, immunohistochemistry and flow cytometry analysis demonstrated an
accumulation of T cells in tumors treated with VC2 compared to PBS-treated tumors. Using
depletion studies and functional assays, we found that VC2 efficacy is dependent on CD8+ Tcells, and that treatment with VC2 promotes tumor specific T cells and reduces the T regulatory
cells (Tregs) population in B16F10n-1 tumor.
In chapter 3, we further investigated whether VC2 could be utilized for the personalization of
cancer vaccines. For this study, we modified VC2, to harbor a fragment of ovalbumin (OVA) on
the viral VP26 capsid protein. Our in vitro growth analysis indicates that both VC2-OVA and
parental VC2 viruses exhibited a similar growth pattern. Results from our prophylactic
vaccination studies demonstrates that intradermal vaccination of VC2-OVA confers significant
protection and prolonged the survival of mice which had been challenged with ovalbuminexpressing B16 melanoma (B16cOVA) cells, but not those mice challenged with the parent
B16F10 tumor cells. Similar results were observed in our E.G7-OVA thymoma mouse model.
This suggests that the anti-tumor immune response induced by VC2-OVAvaccination therapy is
OVA antigen specific and can be applied to other OVA antigens tumor models. On the other
hand, therapeutic vaccination with VC2-OVA led to reduced lung colonization of tumor cells in
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treated mice intravenously challenged B16cOVA cells compared to those vaccinated with parent
VC2 virus. Furthermore, we observed an increase in CD8+ T cells with an effector/memory
phenotype (CD44+ CD62L-) in mice vaccinated intradermally and subcutaneously with VC2OVA, compared to VC2 vaccinated controls mice.
4.3. Conclusions and future directions
The data presented in this dissertation demonstrates that treatment with VC2 results in the
induction of robust antitumor T-cell responses and in addition, can alter the immunosuppressive
TME of B16F10 melanoma tumors. The immunostimulatory component of VC2 further suggests
that this virus may be particularly suited to delivery of heterologous antigens for cancer
immunotherapy.
Future studies will be directed at utilizing single cell transcriptome sequencing (scRNA-seq)
to determine the T cell signatures during VC2 OVT. This approach will reveal the clonality,
transcriptomics and functional states of T cell responses induced by VC2 therapy. In addition, we
will generate a recombinant VC2 expressing B16F10 melanoma tumor associated antigens that
are capable of enhancing the efficacy of VC2 OVT and enhancing the induction of neoantigen
specific T cells. Our model will enable study of the immunological correlates of protection for
VC2 OVT or OVT in general, and this knowledge may be used to inform the rational design of
future, more efficacious OVTs that could potentially used as prophylactic and therapeutic anticancer vaccines.
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